The Danish pharmaceutical company intends to reduce 11% of its workforce, or 9,000 positions, in order to save 8 billion Danish krone ($1.25 billion) a year. Indian workers in Bengaluru have been laid off less than a month after Ozempic manufacturer Novo Nordisk declared it was reducing its worldwide workforce as part of a reorganisation strategy.
At least three people who are aware of the development reported to Mint, saying that it has affected junior-to-mid-level personnel in departments like sales and marketing as well as those in the company’s global business services (GBS) hub, which collaborates with its international teams. According to Mint, the commercial unit, which primarily consists of sales and marketing positions, will lay off at least 100–150 employees.
As part of the worldwide layoffs, they are anticipated to be in junior and middle order. Another official with knowledge of the situation stated that other departments are probably affected as well.
Novo Nordisk Facing with Stiff Competition
The Danish drugmaker planned to cut 9,000 jobs, or 11% of its workforce, in September, which would save it 8 billion Danish krone ($1.25 billion) annually. The announcement came as the company struggles with increasing competition from rivals like Eli Lilly in the highly lucrative obesity segment.
The company said in an emailed response to media queries on the India layoffs that it has announced that the total number of intended workforce reductions globally is approximately 9,000. Out of respect for the employees involved, the company will not share additional details about individual sites or areas.
This process takes time, and the company’ highest priority is to support its employees. The layoffs come as the pharma giant plans to launch its blockbuster once-a-week weight loss drug, Ozempic, in India soon. The Indian drug regulator approved it last month, and the launch is imminent.
Novo Nordisk launched Wegovy, another once-a-week injectable, in India in July even as competitor Eli Lilly’s drug Mounjaro was gaining significant ground.
Reasons forNovo Nordisk’s Layoffs
Since last year, Novo Nordisk’s growth has been hindered by cheaper imitation compounds in the US and fierce competition from Eli Lilly’s medicines, such as Zepbound and Mounjaro. In an effort to streamline its operations, speed up decision-making, and reallocate resources to the company’s expansion prospects in diabetes and obesity, the corporation announced worldwide employment layoffs last month.
Eli Lilly, a competing American pharmaceutical company, gained a first-mover advantage in India in March when it introduced its weight-loss medication, Mounjaro. Analysts predict that the weight-loss medication market in India, which has over 254 million obese people and over 100 million diabetics, would reach INR 10,000 crore in the next two to three years. According to data from Pharmarack, Wegovy had made INR 19 crore in sales as of August, while Mounjaro had made INR 150 crore nationwide.
Quick Shots
•Up to 150 employees to be laid off in India, mainly
in sales, marketing, and Global Business Services (GBS).
•Layoffs part of global workforce reduction
announced in September.
•Eli Lilly’s Mounjaro launched earlier in March,
already leading in sales.
•Sales as of August: Wegovy – INR 19 crore, Mounjaro
– INR 150 crore.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations.
To talk about pharma and medicines in today’s times, the industry is considered one of the most booming industries. These industries have offered a prevalence of contributions to the world of medicine. Medicines and drug usage has been there since immemorial, but the process of manufacturing has changed drastically.
These industries have a lengthy process and go through various stages such as design, formulation, fabrication, withdrawal, dispensation, distillation, and a lot of other things needed for the production of chemical substances.
Dr. Reddy’sLaboratories is dedicated to offering innovative, cost-effective medications for healthier living in the most integrated manner possible. It offers a variety of goods and services, such as APIs, specialised pharmaceutical services, generics, biosimilars, and unique formulations, through its three businesses, Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products.
Let’s dig more into Dr. Reddy Laboratories’ founders, business model, revenue, acquisitions, growth, and more in this article.
This pharma manufacturing company was founded in 1984 by Dr. Kallam Anji Reddy. The company initially started as a supplier for Indian drug manufacturers but shortly diversified its operations to export to other less-regulated markets. The company took advantage to get approval from other drug licensing companies like the U.S Food and Drug Administration (FDA), which resulted in huge profits that led to their formulations and setting up bulk drug manufacturing factories in advanced places.
Dr. Reddy’s main therapeutic interventions are in the areas of dermatology, cancer, diabetology, gastroenterology, oncology, and pain management. It has markets all over the world like in the USA, India, Russia & CIS countries, and Europe. The company has 21 manufacturing facilities spread over 66 countries.
India is one of the top 10 exporters of pharmaceuticals. It supplies 50% of vaccines in the global market, 40% of generic demand in the US, and 25% of all medicine in the UK.
As per a Pharmaceuticals industry report, India’s domestic pharmaceutical market was at $42 billion in 2021. It is predicted to reach $65 billion by 2024, and $120-130 billion by 2030.
Dr. Reddy’s Laboratories is known for manufacturing and marketing a wide range of pharmaceuticals in India and overseas
Dr. Reddy’s Laboratories – Founder
Dr. Kallam Anji Reddy is the founder of Dr. Reddy’s Laboratories.
Dr. Kallam Anji Reddy – Founder of Dr. Reddy’s Laboratories
Dr. Kallam Anji Reddy
Dr. K Anji Reddy was born in 1941 to a modest but prosperous farming family in the Andhra Pradesh hamlet of Tadepalli. His inspiration goes to his father as he grew up watching him make herbal pills and distributed them without charging any penny to the needy ones.
Dr. Anji Reddy completed his schooling at Anapothana Zilla Parishath High School Nutakki. He got his degree in B.Sc. (Tech) from the University Department of Chemical Technology, Mumbai. Soon after graduation, he got his PhD in Chemical Engineering from the National Chemical Laboratory, Pune. After that, he spent six years working for the government-owned Indian Drugs and Pharmaceuticals Ltd (IDPL). This exposure to working at the IDPL fueled his desire to start his own business.
Dr. Kallam Anji Reddy quotes, “It was a dream. It was not a plan on the drawing board, no. But it was a dream.”
For his contributions to the Indian pharmaceutical industry, the Indian Government honoured him with the Padma Shri in 2001 and the Padma Bhushan in 2011. He was also a representative on the Trade and Industry Council for the Indian Prime Minister.
Dr. Kallam Anji Reddy suffered from cancer and lost the battle on 15 March 2013. He died at the Apollo Hospital, Hyderabad. At present, the company is run by his son, Satish Reddy and son-in-law, G.V. Prasad.
Dr. Reddy’s Laboratories – Startup Story and Growth
Soon after the construction of its manufacturing plant at Bollaram, the company commenced its business in 1985. In one year, Dr. Reddy’s Laboratories got listed on the Bombay Stock Exchange and entered the international market during this year with the export of the API Methyldopa.
The company started its first manufacturing of Omeprazole in 1991, which is considered to be the best product worldwide soon after, they entered the Russian market, their first-ever international exposure.
In the late 1990s, Dr. Reddy’s Laboratories US generics market established its offices in New Jersey. Besides their international establishment, the company started manufacturing Biologics to give Indian consumers a taste of high–cost medicines at reasonable prices.
The company introduced the first generic medicine, “Ibuprofen” under its brand in the US in 2008 after experiencing significant growth in the Indian market.
In 2005, Dr. Reddy’s Lab developed India’s first drug for the treatment of diabetic foot ulcers.
To touching a revenue of $1 billion in the mid-2000s, the company made several drugs like antibody biosimilar monoclonal antibodies to treat certain autoimmune diseases to entering into Colombia with a portfolio of high-quality and affordable medicines for cancer patients in 2016, the company has come a long way.
In 2020, to combat Covid-19, Dr. Reddy’s Laboratories made several partnerships from all over the world to bring an innovative therapeutic approach to India. They came up with its first generic Otic suspension product in the U.S.
Last year, the company collaborated with Eli Lilly to export Baricitinib to India. They also collaborated with Merck to provide Molnupiravir to COVID-19 patients everywhere.
The vision of Dr. Reddy’s Laboratories is to live by seven core values, which they give a lot of importance to it. The seven values are:
Sustainability
Integrity and transparency
Safety
Quality
Collaboration and teamwork
Productivity
Respect for the individual
Dr. Reddy’s Laboratories – Name, Logo, and Tagline
Dr. Reddy’s Laboratories – Logo and Tagline
Since it was the dream of Dr. K Anji Reddy to create affordable medicine for every class of people, he started the company with his surname, Dr. Reddy’s Laboratories. The company works with the tagline, “Good Health Can’t Wait.”
Dr. Reddy’s Laboratories – Business Model
Dr. Reddy’s Laboratories’ business model is mostly about research and development, end-to-end production, and cutting-edge digital technology to fulfil its commitments to patients all around the world. Their business model is successful as they produce drugs in bulk size and have in-house R&D centres.
They do business by providing the following services:
India Branded Generics – By developing medicines for acute and chronic diseases, and establishing speciality care, institutional/hospital business, OTC, and eCommerce.
North America Generics – By having establishments in New Jersey, and Canada to offer their affordable healthcare to the world.
Emerging Markets Branded Generics – They have their services in Southeast Asian countries. The company provides medicines – the Association of Southeast Asian Nations (ASEAN), Africa, Australia, and New Zealand; CIS and Romania; China; Latin America and Russia.
Europe Generics – The company also offers its services to give access to affordable and innovative medicines in Europe as well. They have a presence in France, Germany, Italy, Netherlands, Spain, Ukraine, and United Kingdom.
Active Pharmaceutical Ingredients (APIs) – They manufacture bulk drugs or active pharmaceutical ingredients (APIs), which remain a cornerstone of the company.
Biologics – The company generates and markets a variety of immunology and oncology-related biosimilar medicines. This is the most integrated part of the company.
Aurigene Pharmaceutical Services – With scale-up and commercial manufacturing facilities in India, the UK, Mexico, and the US, Dr. Reddy’s Aurigene Pharmaceutical services provide discovery and development services at top-notch facilities in India.
Dr. Reddy’s Laboratories – Revenue
Dr. Reddy’s Laboratories Revenue from FY2015 to FY2022 (Revenue in billion INR)
The company mostly gets 45% earnings from North America Generics, then 18% from India, 19% from Russia, 12% from Europe, and 6% from the rest of the world.
The company has generated $74.9 billion from NAG, $16.6 billion from Europe, $45.7 billion from emerging markets, and $42 billion from India in FY22.
Dr. Reddy’s Laboratories recorded a revenue of $2.83 billion for FY22 which was an 8.94% increase from $2.59 billion in FY2021.
Dr. Reddy’s Laboratories launched Hyperinjection in US. The announcement of the company’s joint launch of Treprostinil injection in the US market with its subsidiaries came in April of 2023.
Gummies
CeleHealth Kidz Immuno Plus Gummies were introduced to the Indian market in July, 2023 by Dr. Reddy’s Laboratories. The product attempts to meet the dietary needs related to the increasing worries about kid immunity in India.
Celevida wellness
Dr. Reddy’s Laboratories Ltd. stated that Svaas Wellness Limited, a wholly-owned subsidiary, has launched “Celevida Wellness,” the company’s first direct-to-consumer (D2C) e-commerce website for diabetic patients on October, 26, 2023.
Dr. Reddy’s Laboratories – Funding
Company has raised $6 million in two funding rounds.
Date
Funding Round
Amount
Oct 3, 2022
Post-IPO Equity
–
Dec 1, 2001
Post-IPO Equity
$6M
Dr.Reddy’s Laboratories – Investments
Dr.Reddy’s Laboratories has Invested in one company to date:
Date
Funding Round
Company Name
Amount
Sep 30, 2005
Series A
Perlecan Pharma
$52.5M
Dr. Reddy’s Laboratories – Challenges Faced
The manufacturing business is the toughest business to operate especially in medicine and drugs. Dr. Reddy’s Laboratories have had faced challenges in its journey. There were a few controversies in which the company was caught up. The company had quality problems in its Mexico unit and a few fatal accidents.
Recently, the company announced a 76% year-over-year (YoY) decline in profit after tax (PAT) to Rs 88 crore in Q4FY22 due to pricing pressure in North America and Europe, decreased export benefits, and a rise in inventory reserves.
Dr.Reddy’s Laboratories – Partnership
Shanghai Junshi Biosciences Co., Ltd
Dr. Reddy’s Laboratories and Shanghai Junshi Biosciences Co., Ltd. has partnershiped on Augut, 5, 2023 to develop and market toripalimab, the anti-PD-1 monoclonal antibody, in South Africa, India, Latin America, and, upon Dr. Reddy’s election, Australia, New Zealand, and other nations.
Amazon Web Services
Amazon Web Services (AWS) has revealed that Dr Reddy’s Laboratories Limited (Dr Reddy’s), has partnershiped with AWS on July, 10, 2023 as its preferred cloud provider in order to facilitate the provision of new and reasonably priced medicines.
Theranica
Theranica, an Israeli digital therapeutics firm, has signed a strategic partnership and supply deal with Dr. Reddy’s Laboratories Ltd. for the exclusive marketing and distribution of its FDA-approved Nerivio in India.
Dr. Reddy’s Laboratories – Shareholders
The company has several shareholders. The following are the shareholders who hold 1% or more of the equity shares as of March 2022:
Name
Number of Shares
%
Dr. Reddy’s Holdings Limited
41,325,300
24.83
Life Insurance Corporation of India
8,769,499
5.27
SBI-ETF Sensex
4,245,926
2.55
Aditya Birla SunLife Trustee Private Limited
3,631,279
2.17
First Sentier Investors ICVC-Stewart Investors
3,500,511
2.1
ICICI Prudential Value Discovery Fund
3,224,070
1.92
Government of Singapore
3,004,517
1.81
ICICI Prudential Life Insurance Company Limited
2,743,177
1.64
NPS Trust and their associates
2,488,266
1.48
UTI-Mastershare Unit
1,991,477
1.19
HDFC Trustee Company
1,700,213
1.02
Government Pension Fund Global
1,677,349
1.01
Mirae Asset Tax Saver Fund and their associates
1,668,396
1
Dr. Reddy’s Laboratories – Mergers and Acquisitions
The company has made 6 acquisitions till now and is also open for M&A and is waiting for the right opportunity. The acquisitions are:
Dr. Reddy’s Laboratories – Awards and Achievements
The company has got several awards for its performance in the pharmaceutical industry. Below is the list of awards won by Dr. Reddy’s Laboratories:
Top Employers Institute – recognised as Top Employer in South Africa
Sustainability 4.0 Awards 2022 – Sustainable Corporate of the Year award
Dow Jones Sustainability Index 2021 – Among top 10 leaders globally; featured for 6th year in a row in the Emerging Markets category
Member of the Sustainability Yearbook 2022
Bloomberg Gender-Equality Index 2022 – the only Indian pharma company in the index
CII SCALE Award 2021 – for excellence in logistics and supply chain for the 7th consecutive year
CII Industrial Innovation Awards 2021
Global Generics & Biosimilars Awards 2021
United Nations Women’s Empowerment Principles Awards – 2nd runner-up in the Gender Inclusive Workplace category in Asia-Pacific
Indo-American Chamber of Commerce 2021
Economic Times – Futurescape 8th Sustainability Index Report 2021
Dr. Reddy’s Columbia – Great Place to Work in 2021
Dr. Reddy’s Laboratories – Future Plans
The company is aiming to be among the top 5 drug maker companies in the domestic market by planning mergers and acquisitions to up its game.
The co-chairman and managing director of Dr. Reddy’s Laboratories,GV Prasad said in an interview, “Getting into the top 5 is our aspiration. On an organic curve, you can’t reach there (top five). We are open for M&A but for the right price and buttressed by organic execution. We have to pull all the levers”.
FAQs
When was Dr. Reddy’s Laboratories founded?
Dr. Reddy’s Laboratories was founded in the year 1984 and is headquartered in Hyderabad.
Who is the founder of Dr. Reddy’s Laboratories?
Dr. Kallam Anji Reddy is the founder of Dr. Reddy’s Laboratories.
What was Dr. Reddy’s revenue in 2022?
Dr. Reddy’s Laboratories recorded revenue of 2.8 billion USD in FY2022.
What was Dr. Reddy’s Laboratories’ recent acquisition?
Dr. Reddy’s Laboratories’ most recently acquired Germany-based Nimbus Health GmbH. The company announced the agreement of acquisition in February 2022.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. Abbott India Ltd has approved the content in this post.
The character of the pharma industry is such that many people tend to think of it as a very different industry from the rest. It is perhaps one of the most developed sectors in recent times.
Talking about the pharmaceutical industry,Abbott Laboratories is one such company that has made a substantial global impact with its innovative pharma and medical products. Its global headquarters are present in Abbott Park, Illinois, United States. The company is spread across countries in Asia Pacific, Europe, the Middle East, South Africa, and the Americas. Founded in 1888 by Chicago medic Wallace Calvin Abbott, Abbott Laboratories has made a gigantic name for itself in India as well, with its subsidiary Abbott India Limited, which has its headquarters in Mumbai.
Dive into this article for further information on Abbott India Ltd. Read about its mission and vision, key products of Abbott India, business and revenue model, CSR activities, and more.
Abbott India Limited is a subsidiary of Abbott’s international pharmaceutical business in India. It is one of the country’s fastest-growing pharmaceutical firms today. Boots Pure Drug Company (India) Ltd was the initial name under which Abbott India Ltd was founded in 1944. It runs a production plant in Goa as well as a number of independent contractors and third-party producers located throughout the nation.
Abbott India Limited, an Abbott Laboratories subsidiary with its headquarters in Mumbai, offers reliable, high-quality medications in a variety of therapeutic areas, including women’s health, gastroenterology, cardiology, metabolic disorders, and primary care.
Abbott India Ltd is devoted to giving Indians access to high-quality healthcare through a combination of international and domestic goods. The company has its development and medical team that generates products and clinical trials that are specifically suited to the demands of the Indian market. Its staff members try to create high-quality, high-volume formulations utilizing methods that are economical. Additionally, Abbott’s skilled staff members are committed to guaranteeing adherence to global quality standards.
Some of Abbott’s well-known products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip in the medical equipment, diagnostics, and nutrition product businesses.
Abbott India’s CSR Activities
Abbott India is also involved in many corporate social responsibility activities that focus the society in general.
Its therapy-shaping efforts are intended to enlighten and assist individuals in making educated decisions, dispel common misconceptions about illnesses, and increase accessibility and effectiveness. It has set up health clinics like Fibroscan and Liver clinics to help provide a quick, reliable, and timely diagnosis to people. Vaccination outreach programs to create awareness of flu. Abbott India has reached out to parents across more than 50 schools to create awareness and stress the importance of flu vaccines. More than 500 Menopause clinics were established pan India by Abbott India. The company has also executed around 100+ Pausetive Talks (awareness on menopause symptoms) for women across India in 12 regional languages, both digitally and physically.
Abbott India Ltd. – Industry details
India’s pharmaceutical sector is predicted to be worth $65 billion by 2024 and $130 billion by 2030. India’s pharmaceutical sector is currently worth $50 billion.
Patient expenditure on healthcare and medications is anticipated to increase for non-COVID-19 therapy as India’s economic growth is anticipated to continue.
Dr. Wallace Calvin Abbott was born in 1857. He is a graduate of the University of Michigan. When he founded the Abbott Alkaloidal Company, Dr. Abbott was a practicing physician. He was one of the first American doctors to use a novel method to distill alkaloids, the components of medicinal plants that have a therapeutic effect into a solid form like morphine, quinine, strychnine, and codeine. This strategy was helpful because it gave patients more dependable and efficient dosing. The business relocated from Ravenswood to North Chicago, Illinois, in 1922.
Abbott Laboratories was one of the forerunners of the scientific practice of pharmacy under the visionary direction of Dr. Abbott, and it expanded to address increasing global health demands by supporting new fields of medical research.
Vivek V Kamath
Vivek V Kamath – Managing Director, Abbott India Limited
Vivek V Kamath is the Managing Director of Abbott India Ltd. He has a degree in science with a focus on microbiology and a Master’s in Management with a focus on marketing. Mr. Vivek has more than 30 years of extensive and varied expertise in the healthcare industry, including the pharmaceutical, over-the-counter, and diagnostic industries. He has held many top leadership roles in reputable pharmaceutical firms, both Indian and MNCs, in a variety of geographical locations. Mr. Vivek also possesses significant functional knowledge in the fields of strategy, marketing, sales, and general management. He worked with MSD Pharmaceuticals, Roche Diagnostics in India, Novartis in Singapore, Ranbaxy, Pfizer in India, Fulford in India, Wockhardt, and Johnson & Johnson before joining Abbott.
Rajiv Sonalker
Rajiv Sonalker – CFO and Whole-Time Director, Abbott India Limited
Rajiv Sonalker is the whole-time Director and CFO of Abbott India Ltd. He is a fellow member of the Institute of Chartered Accountants of India and holds a Bachelor’s Degree in Science from the University of Bombay. Rajiv Sonalker served as Director of Finance at Bristol-Myers Squibb before joining Abbott India. In Germany and India, Rajiv has also worked with Voltas Ltd., Johnson & Johnson, and Sanofi-Aventis.
Abbott India Ltd. – Startup Story | How It Began?
The story of Abbott India began in the 1940s. The origin of the company is when Dr. Wallace Calvin Abbott founded its parent organization Abbott Alkaloidal Company in 1888. It was during this time when the production of “alkaloidal” medicine granules was introduced, which made it a big hit in the market. After making sufficient sales in the USA, Abbott established its first overseas affiliate in London in 1907; the company then acquired a Montreal, Canada, affiliate. Boots Pure Drug Company (India) Ltd. was the initial name under which Abbott India Ltd. was formed on August 22, 1944. On November 1st, 1971, the business was renamed The Boots Company (India) Ltd; on January 1st, 1991, it became Boots Pharmaceuticals Ltd. The name was changed to Knoll Pharmaceuticals Ltd on October 31, 1995, and then to Abbott India Ltd on July 1, 2002.
17 new products were introduced by Abbott India during the fiscal year that concluded on March 31, 2016, and they collectively generated 1.9% of the company’s net sales. The firm and Bharat Biotech India Limited entered into a license agreement during the reviewed year to commercialize vaccines in the immunology category.
The mission statement of Abbott India is, “to build life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines, and breakthroughs to manage your health.”
Abbott India Ltd. – Name, Tagline, Logo
Abbott India Limited Logo
Before Abbott India, the company’s name was Knoll Pharmaceuticals Ltd. The name was changed in 2002.
The tagline of Abbott Laboratories is, “Live Your Best Life, Now And In The Future”
Abbott India Ltd. – Business Model
Diagnostics, medical equipment, branded generic drugs, and nutritional goods make up the core businesses of Abbott, which have been expanded via acquisitions. The company through its subsidiary, Abbott India creates and sells more than 600 goods for medical professionals that support Indians’ overall health and well-being.
The extensive pharmaceutical portfolio of Abbott in India covers the complete spectrum of healthcare requirements for all phases of life, from illness prevention to treatment and cure. Abbott Healthcare Solutions represents one of the largest pharmaceutical portfolios in India, including some of the market’s most dependable goods. In the fields of dermatology, diabetes, cardiology, gastrointestinal, central nervous system, pain management, and orthopedics, it is widely regarded as a market leader.
In India, the top of their respective categories is occupied by trademarks like Stemetil, Haemaccel, Kenacort, Paraxin, and Neomercazole. Abbott India’s business also includes providing high-quality healthcare to those living in ultra-urban areas where access to these quality healthcare solutions is a challenge. With a high-quality, reasonably priced portfolio of products in the therapy areas of pain management, gastroenterology, and anti-invectives for diseases like typhoid, malaria, and respiratory infections, Abbott True Care is assisting in improving the health and well-being of the people in extra-urban towns.
Abbott India’s main business operations are divided into the following categories:
Nutrition – This is further divided into categories like Adult Nutrition (Ensure and ZonePerfect), Child Nutrition (Isomil, and Gain) Infant Nutrition, and other medicinal nutrition
Diagnostics – with focus areas like Core labs, Molecular, and Point of Care
Established Pharmaceuticals – branded generic drugs
Medical devices – offering high-end medical devices for diabetic care, vascular care (coronary and endovascular), rhythm management, and electrophysiology.
The superior financial success has constantly been a result of the robustness of its business model.
Abbott India Ltd. – Revenue Model
Abbott India Ltd. made 11.4% of its Revenue from Operations. For FY 2021-2022, the company has delivered impressive results with 14.1% growth in revenue and 15.6% in net profits over the previous year. The company mostly generates its revenue from its diversified pharmaceutical portfolio.
Abbott India Ltd. – Growth
With a 14.1% growth in revenue (from ₹4,310 crores in FY21 to ₹4,919 crores in FY22), Abbott India has added 10 new items to its major portfolios in the therapeutic areas of women’s health, gastroenterology, central nervous system, multi-specialty, and vaccines. It conducts business in Nepal, Sri Lanka, Maldives, and Bhutan. Abbott India’s emphasis on expanding its business in these nearby nations and helping people through its high-quality products is also growing. It has a robust distribution network of more than 8,600 stockists and 60 lacs, retailers.
Abbott India Ltd. – Advertisements and Social Media Campaigns
In 2020, Abbott India launched the ‘Don’t Wait for Life’ campaign to highlight the importance of health challenges through technologies and solutions. The advertising campaign emphasizes the value of pursuing one’s dreams without sacrificing the life one is already living. The ad talks about Abbott’s groundbreaking cardiac pumps enabling people to continue living normally even when they have heart failure.
The campaign was launched by a series of four videos that depict the stability of people with heart problems and diabetes, which are considered highly prevalent non-communicable health conditions in India.
Abbott India Ltd. – Awards and Achievements
The list of awards and achievements won by Abbott India are:
Abbott India Ltd won the ‘GOLDEN PEACOCK HR EXCELLENCE AWARD’ For the second consecutive year from the Institute of Directors
Abbott India Ltd was recognized by Avatar and Working Mothers as the “Best Companies in India”
Abbott India Ltd won the “Best Places to Work” For 8 consecutive years by Business Today
Abbott India’s Goa plant received the prestigious Abbott Global EHS Excellence award for upgrading the fire-fighting facility without business interruption. The plant also received the Best Plant award from Abbott Global.
Abbott India Ltd. – Competitors
Abbott India competes with the following top competitors:
Abbott India wants to keep placing a priority on developing novel medicines. The company further plans to introduce cutting-edge goods and services to the market. It believes this introduction is essential if it wants to revolutionize Indian healthcare.
FAQs
Who is the Managing Director of Abbott India Ltd.?
Mr. Vivek V Kamath is the Managing Director of Abbott India Ltd.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Alembic Pharmaceuticals.
Pharmaceutical manufacturing goes through many stages before producing a single medicine. This industry is by far one of the most successful industries of today. The success rate of these pharmaceutical manufacturing has resulted in outstanding progress in the medical world.
With its headquarters in Vadodara, Alembic Pharmaceuticals Ltd. is a global pharmaceutical firm based in India. Founded in 1907, Alembic Pharmaceutical produces pharmaceutical goods, pharmaceutical ingredients, and pharmaceutical intermediates. It is also referred to as the market leader in India’s macrolides anti-infective medication category. Alembic Pharmaceuticals belongs to the Alembic Group, which was founded by Prof. T.K. Gajjar, Prof. Kotibhaskar, and B. D. Amin.
Learn all about Alembic Pharmaceuticals’ success story, its startup story, mission, and vision, and its business and revenue model.
Alembic Pharmaceuticals Ltd. works on the production and marketing of Indian formulations, active pharmaceutical ingredients, international generics, and pharmaceutical intermediates. The company’s corporate office and headquarters are located in Vadodara, Gujarat, India, while its production facilities are spread out between Sikkim and Panelav, both in Gujarat. Active pharmaceutical ingredients (APIs) and formulation production are handled by its Panelav factory, while formulation production for India and unregulated export markets are handled by its Sikkim plant. Recently, the company’s production capacity was increased by the addition of three new plants for oral solids and injectables for cancer, general injectables, ophthalmology, and oral solids, bringing the total to six state-of-the-art facilities that epitomize manufacturing excellence.
Alembic Pharmaceuticals is among the most reputable suppliers of specialty medications in India for a range of acute and chronic treatments. In the domestic market, it provides a range of high-quality items that address ten therapeutic categories. Alembic Pharmaceuticals is renowned for providing its customers with deliveries on time.
Alembic Pharmaceuticals’ CSR initiatives
The Alembic CSR Foundation was founded in 2015 to uplift and strengthen communities across various areas of Education, Health, and Overall Community Development.
The company’s plantation initiatives have resulted in 1,300 saplings being planted over the past 5 years in 4 panchayats of the Panchmahals district, including 100 saplings planted in Gopipura village during 2020-2021. Alembic’s CSR foundation has built 242 domestic toilets in the Karkhadi and Pindapa panchayats in the Vadodara district as part of its sanitation activities. In the Vaseti Panchayat villages of Tajpura, Dadiyapura, and Shivjipura, it has also constructed 346 domestic toilets.
Alembic Pharmaceuticals – Industry details
Over the past two decades, India’s pharmaceutical business has expanded at a compounded growth rate of 16% for exports and 11% for the domestic market.
Through 2025, the worldwide pharmaceutical industry is anticipated to expand at a 3-6% CAGR, with a projected market value of $1.6 trillion. This does not include COVID-19 vaccine investment, which is expected to total $157 billion overall through 2025.
Alembic Pharmaceuticals – Founder and Team
Alembic Pharmaceuticals is managed by Chirayu Amin, the Chairman & CEO of the company.
Chirayu Amin- Chairman & CEO
Chirayu Amin
Chirayu Amin is a multimillionaire businessman from India who also oversees cricket. Amin has guided the organization through the shifting demands of modern business while maintaining its legacy.
He got his MBA degree from Seton Hall University. Furthermore, Chirayu Amin served as the Federation of Indian Chambers of Commerce’s chairman. Malika Chirayu Amin, his wife, has been listed by Kotak Wealth Hurun as one of India’s wealthiest women in 2020.
Chirayu was also the Baroda Cricket Association’s president. He has received the Federation of Gujarat Industries (FGI) Lifetime Achievement Award in January 2021. According to Forbes, Chirayu Amin’s net worth as of May 2021 was US$1.8 billion.
Pranav Amin
Alembic Pharmaceuticals Ltd’s Managing Director, Pranav Amin, is in charge of the division’s global business operations. He is a graduate of Thunderbird University in the United States with an MBA in International Management and a degree in Economics/Industrial Management from Carnegie Mellon University in Pittsburgh, USA. Pranav Amin is considered a fantastic people leader who directs the company via participation, empowerment, and autonomy.
Alembic Pharmaceuticals – Startup Story
In 1907, Alembic Chemical Works, which is now Alembic Pharmaceuticals Ltd., began producing tinctures and alcohol at its Vadodara facility. The business subsequently started producing sulfur medications, vitamins, tonics, and cough syrups around the 1940s.
Additionally, Alembic started producing penicillin in the 1960s. Lal Bahadur Shastri, the Indian Prime Minister at the time, dedicated this Alembic factory to the production of penicillin in 1961.
The pharma company immediately started producing vitamin B12 in large quantities in 1967.
In the field of antibiotics, Alembic started producing erythromycin in India for the first time in 1971, not long after the manufacturing of penicillin was started. Alembic also created and introduced the erythromycin brand “Althrocin.” Althrocin surpassed all other erythromycin brands in sales in India in 1997.
After a few years, Alembic got ISO 14000 accreditation in 2000 for its Vadodara plant. Following the distribution of 133,515,914 equity shares worth $2 each to the shareholders of Alembic Ltd. in 2010, Alembic Pharmaceutical Ltd. separated from Alembic Ltd. As a result, Alembic Ltd.’s ownership of Alembic Pharmaceutical decreased from 100% to 29.18%.
Alembic Pharmaceuticals Ltd.’s equity shares were placed on the Bombay Stock Exchange and the National Stock Exchange of India in 2011.
Around 2012, the company revealed the dermatology department in Indian markets with eight new products. In 2017, Alembic Pharmaceuticals based the manufacturing facility for Oncology medicines in presence of the then Hon’ble Chief Minister of Gujarat, Shri. Vijay Rupani.
Alembic gained a $250 million sales milestone in the USA front end.
Alembic Pharmaceuticals – Mission and Vision
Alembic Pharmaceuticals’ mission is, “To improve healthcare with innovation, commitment, and trust.”
The company believes that the four pillars of quality, capability, customer centricity, and diversity are the key enablers for its future growth.
Alembic Pharmaceuticals – Name, Tagline, Logo
Alembic Pharmaceuticals Logo
Alembic Pharmaceuticals – Business & Revenue Model
Alembic Pharmaceuticals Ltd. runs its business as a vertically integrated pharmaceutical company. Each of the company’s business areas may benefit from the premium items in its varied range, which command greater margins.
Alembic deeply invests in developing a portfolio of specialized, specialist medications that offer chances for long-term revenue development. It takes advantage of its manufacturing and intellectual edge, through strategic acquisitions that offer prospects for internal product development and value enhancement.
Domestic Business:
Alembic offers products in 10 therapeutic areas including Cardiology, Orthopaedic, Ophthalmology, Nephro/Uro, Anti-Diabetic, Gynaecology, Gastrology, Dermatological, Anti-Infective, Cold, and cough with 185 brands in the market.
Most of its caters to several chronic and acute therapies and around 1,75,000 doctors in India.
It has two R&D centers situated in Vadodara (Gujarat), and Hyderabad (Telangana)
Alembic’s formulation facility is located in Sikkim, Panelav, Karkhadi
Alembic’s two brands are in the top 300
1.4% market share in the Indian pharma space
Alembic APIs are supplied to formulators in over 60 countries across the globe
Alembic has generated Rs 1,497 crores (2020-2021) in domestic business
International Business
Alembic is present in the US, Europe, Canada, Australia, Brazil, South Africa, and other markets
Offers diversified products in various therapeutic areas
The company has launched more than 90 products in the USA till now
It has one R&D facility in New Jersey, USA
Alembic generated around Rs 2,942 crores (2020-2021)
The company’s international business grew by 62% in Quarter 1 FY21 on a Y-o-Y basis, this excludes the USA.
As per reports, Alembic spent around 12.4% of its revenue on R&D activities during 2020-2021 to upscale its generic business to the international markets.
Alembic Pharmaceuticals – Growth
Alembic Pharmaceuticals claims that it had enormous growth and a huge increase in market share for Azithral OSD. The company also established itself as a serious player on a worldwide scale since azithromycin was a crucial drug in the management of COVID-19. With a 30% market share of the domestic formulation market in India, it is one of the biggest makers of azithromycin.
The implementation of the Laboratory Information Management System (LIMS) in its plants to ensure smooth workflow and data tracking, as well as the Quality by Design (QbD) initiative to improve the safety and efficacy of its products, are just a few of the significant initiatives carried out by the company in the recent years.
Alembic Pharmaceuticals – Mergers and Acquisitions
During its 115 years of legacy, Alembic has acquired some renowned business operations. The year 2012 saw the announcement of Paragraph IV ANDA litigation between Alembic Pharmaceuticals and Breckenridge Pharmaceutical, Inc., and Pfizer about desvenlafaxine (Pristiq). Additionally, Alembic and AccuBreak Pharmaceuticals Inc. engaged in product development and license arrangement.
Alembic Pharmaceuticals and Ranbaxy Pharmaceuticals Inc. engaged in an out-licensing arrangement in 2013 to allow Alembic Pharmaceuticals to commercialize its medications in the USA. Later after one year, Alembic Pharmaceuticals entered into joint ventures with Adwiya Mami SARL Algeria through its wholly-owned subsidiary Alembic Global Holdings, expanding its business in Algeria. Besides this, Alembic also signed an exclusive contract with Novartis around 2015, expanding its business in Switzerland.
Here’s the list of acquisitions made by Alembic Pharmaceuticals Ltd.:
Date/Year
Acquiree Name
Amount
March 29, 2022
Aleor Dermaceuticals
–
November 1, 2017
Orit Laboratories
–
2007
Dabur’s non-oncology formulation business
Rs 150 crores
Alembic Pharmaceuticals – Funding and Investors
In a qualified institutional placement (QIP) on Thursday, Alembic Pharma collected Rs 750 crore from investors including Tata Mutual Fund, HDFC Life, Sundaram, Bajaj Life, and Nippon India Mutual Fund.
Alembic Pharmaceuticals – Awards and Achievements
Alembic Pharmaceuticals has won many awards and achievements, those are:
Excellent Efforts in Risk Management Award
Alembic Pharmaceuticals was listed in Forbes’ 2016 list of “India’s Super 50 Companies.”
Job Safety Analysis (JSA) Finished as the first runner-up in Job Safety Analysis (JSA) at CII Industrial Safety Summit 2016
Gujarat Best Employer Brand Award -Recognised for the ‘HR Event of the Year’ and ‘Outstanding Contribution to the cause of Education at the Gujarat Best Employer Brand Awards 2017
Alembic Pharmaceuticals received the Thomson Reuters Top 50 Indian Innovators Award in 2015
Alembic Pharmaceuticals – Competitors
Below is the list of competitors of Alembic Pharmaceuticals:
Presently, Alembic Pharmaceuticals is establishing new capacities and funding R&D initiatives with more favorable risk-return profiles. In addition, its consumer interaction skills are driven by its US marketing team, who also assists them in adding more value. It further plans to take advantage of scale economies and guarantee an adequate supply for its clients by gradually investing in boosting capacity.
FAQs
Who is the CEO of Alembic Pharmaceuticals?
Chirayu Amin is the CEO of Alembic Pharma.
Is Alembic Pharma an MNC?
Yes, Alembic Pharma is an Indian Multinational Company based in Vadodara, Gujrat.
What is the rank of Alembic Pharmaceuticals?
Alembic Pharma ranks 18 in India in terms of market cap.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Laurus Labs Ltd.
Pharmaceuticals are becoming an essential component of daily living. By saving people from the terrible grip of fatal illnesses, they are improving public health. The industry is growing each day, with various pharma companies indulging in developing new and innovative pharma products.
Laurus Labs Ltd. is an international pharmaceutical and biotechnology firm based in Hyderabad, India. It has three manufacturing units in Visakhapatnam, Hyderabad, and Bengaluru. Founded by Dr. Satyanarayana Chava, the pharma company focuses on creating APIs, custom synthesis, generic medications, and biotechnology. Laurus Labs is a top provider of APIs for international pharmaceutical firms operating all over the world in the ARV therapeutic arena.
Know all about Laurus Labs’ funding, founders, mergers and acquisitions, business and revenue model, how it started, marketing strategies, and more.
The Hyderabad-based pharma company, Laurus Labs provides a wide range of integrated products and services to the worldwide pharmaceutical sector. With a top-notch infrastructure, top-notch staff, and a commitment to knowledge, innovation, and excellence, Laurus Labs quickly became a market leader in the production of high-quality APIs, a top choice for NCE development and manufacturing, and a reliable supplier of specialty ingredients for the nutraceutical sector. It offers its APIs in almost 56 countries. Furthermore, its main priority includes anti-retroviral, Hepatitis C, and Oncology drugs. API refers to the Active Pharmaceutical Ingredients that are used in medicines.
The company works with the top 10 generic pharmaceutical firms in the world. It has about 55+ cutting-edge R&D centers in India and US. In addition, it has more than 90 APIs manufactured at its 8 manufacturing facilities. Laurus Labs has more than 750 research scientists in their team of more than 4000 employees. It has received certification and approval from the WHO, USFDA, NIP Hungary, PMDA, KFDA, and BfArM for its facilities. Laurus Labs’ ability to manufacture APIs and conduct robust R&D has allowed them to expand quickly and globally.
Laurus Labs CSR activities
Following the provisions of the Companies Act of 2013 and the Companies (Corporate Social Responsibility) Rules of 2014, which were issued by the Central Government, Laurus Labs has implemented a Corporate Social Responsibility (“CSR”) policy. Its CSR efforts are generally concentrated on programs that support the environment, healthcare, and education, especially in the regions close to our industrial locations. The CSR Committee of its Board keeps an eye on all of its CSR initiatives. Laurus Labs’ Environmental, Social, and Governance (ESG) operations, which are a crucial component of its strategy and a significant reputation driver, also saw additional advancement. The ESG initiatives of Laurus Labs remained in the top 25% of global pharmaceutical businesses according to MSCI’s evaluation of ESG risk tolerance, with an “A” grade.
Laurus Labs – Industry details
The year 2020 has been a year of rapid change for the pharma industry and the world. Despite the challenges, the pharma industry is one of the crucial industries in the world that has been growing with each passing day. It is predicted that the industry’s market value will reach around $130 billion by 2030.
Laurus Labs – Founders and Team
Laurus Labs is founded by Dr. Satyanarayana Chava in 2005.
Dr. Satyanarayana Chava
Dr. Chave graduated from Andhra University with a science bachelor’s and master’s degree. From 1985 until 1992, he worked as a research scholar at the College of Science and Technology at Andhra University, where he later earned his Ph.D. He has been part of the company since January 21, 2006, as its Whole-Time Director. Besides, Dr. Chave is the CEO of Laurus Labs Ltd.
Vantaram Venkata Ravi Kumar
Mr. V V Ravi Kumar serves as Laurus’s executive, full-time director, and Chief Financial Officer. He has been a director of the firm since November 30, 2006. Mr. V V Ravi Kumar’s responsibilities include overseeing the finance and human resources departments as well as the supply chain management division for a sizable period. Laurus Labs – Startup Story
Laurus Labs – Startup Story
Laurus Labs began its pharmaceutical journey by opening up its first R&D center in Hyderabad in 2005. Within four years, the company commenced its first international business by launching its first product in Europe. Thereafter, it entered into an agreement with an international organization to manufacture and sell its products in the ARV segment. From the 2010s onwards, Laurus Labs made some acquisitions to expand its operations.
Laurus Labs opened many more manufacturing facilities in and around Visakhapatnam, Hyderabad, and Bangalore. Today, the company has made a revenue of $48 billion and has three subsidiaries; Laurus Generics, Laurus Synthesis, and Laurus Bio.
Laurus Labs – Mission and Vision
Laurus Labs’ vision tells, “To become a leading player in offering integrated solutions to global pharmaceutical needs in creating a healthier world.”
The company aspires to offer affordable pharmaceutical products all over the world.
The mission statement of Laurus Labs reads, “We constantly strive for innovation to enhance quality and to provide affordable integrated pharmaceutical solutions to facilitate wellness and well-being across the globe.”
Laurus Labs – Name, Tagline, Logo
The tagline of Laurus Labs is, “Knowledge. Innovation. Excellence.”
Laurus Labs – Business & Revenue Model
Laurus Labs’ business operations are divided into four segments. These are; contract development and manufacturing (CDMO)-Synthesis, generic formulation (FDF), generic APIs, and biotechnology.
The company provides a wide range of integrated products and services to the international pharmaceutical sector. The culmination of its comprehensive approach which has been successfully carried out over these many years is the transition from APIs to formulations to synthesis enterprises. Throughout the whole value chain of the product, its four business units address a broad range of therapeutic uses.
Generic formulation (FDF)
The US Food and Drug Administration permitted Laurus Labs to sell hydroxychloroquine pills in March 2020. The business declared that it will provide hydroxychloroquine for COVID-19 prevention clinical studies. Some of the generic formulation products offered are:
Anti-retroviral, Anti-diabetic, Cardiovascular, Proton Pump Inhibitors, and Central nervous system. Generic formulation contributes about 38% of its revenue. FDF business increased 13% year over year to Rs 1,880 core. (FY21-22).
CDMO – Synthesis
Laurus Labs had a new CDMO multi-year cooperation agreement for specialized APIs signed with a top Global Lifesciences firm. The business’ CDMO division is called Laurus Synthesis. [15] The three most significant markets for Laurus Synthesis are the United States, the European Union, and Japan. Due to the acquisition of new clients and growing demand from current clients, the company’s CDMO business expanded steadily at 77% y-o-y. The CDMO-Synthesis business generates 19% of revenue for the company.
Generics – API
With one of the greatest HiPotent API capabilities in India, Laurus Labs claims to be the “world’s largest third-party API provider for antiretrovirals.” In addition, the business produces cancer and cardiovascular APIs, which Laurus Labs sells to nine of the top ten generic pharmaceutical firms worldwide. Generics- API business is the company’s highest source of revenue, with 41% revenue contribution.
Laurus Bio
The company’s biotechnology division is called Laurus Bio. By purchasing the Indian biotech firm Richcore in 2020, Laurus Labs entered the biotechnology industry. Laurus Labs provide novel protein companies and bio-manufacturers with comprehensive fermentation-based product development and manufacturing expertise, as a service (CDMO), including clone development, strain engineering, process development, scale-up, and large-scale commercial manufacturing. It further supports its customers at every stage of the microbial precision fermentation value chain. Revenues for 2021–22 increased significantly by over 70% over the pre-acquisition annualized run-rate, driven by appealing market possibilities. Laurus Bio recorded Rs 100 crores in sales. It contributes about 2% of the revenue for company.
Laurus Labs – Growth
In 2021–2022, the formulation division reported a 13% increase in sales to Rs 1,880 crores. Oncology API and other API sales also grew well, with a solid order book supporting a positive growth forecast. Since Laurus is a fully integrated participant in ARV formulations, it thinks it will be able to handle any price difficulties in the upcoming quarters. Laurus Labs’ revenue increased by 3% to Rs 4,936 crores. This happened because of the company’s strong FDF performance and exceptional CDMO business growth.
Laurus Labs – Funding and Investors
Over the course of 3 rounds, Laurus Labs has raised a total of $148.1 million in investment. Their most recent round of investment, a Post-IPO Equity round, was raised on December 6, 2016. Laurus Labs is funded by three investors. The three investors are; Goldman Sachs, Warburg Pincus, and Eight Roads Ventures.
Headquarters
Chandigarh, India
Sector
Pharmaceutical manufacturing
Type
Private
Founder
Sandeep Khajuria
Founded
2011
Revenue
Rs 100 crores (approximately)
Website
www.innovexia.com
Laurus Labs – Mergers and Acquisitions
Richcore was bought by Laurus Labs on November 26, 2020. Laurus Labs paid $2.5 billion to purchase Richcore. Richore is a Bangalore-based company that creates new enzyme applications for the food, water, and energy industries.
Laurus Labs – Awards and Achievements
Here’s the list of awards and achievements received by Laurus Labs are:
Emerging Company of the Year 2021 Awarded by Economic Times – Corporate Excellence Awards
E&Y Entrepreneur of the Year 2021 presented for Healthcare and Life Sciences segment
Laurus Labs received Great Place to Work For the third consecutive time in a study conducted by the Great Place to Work Institute (2021-2022)
Laurus Labs won the Business Person of the Year 2021 Awarded by Sakshi Excellence Awards
Great Place to Work Recognised Dr. Satyanarayana Chava, Founder & CEO as one of India’s best Leaders in Times of Crisis 2021
Laurus Labs – Competitors
Below is the list of top competitors of Laurs Labs:
By making investments in backward integration initiatives to build more API and FDF capacity in non-ARV infrastructure, Laurus Labs continues to fortify its position as a competitive integrated pharmaceutical company. Laurus Labs’ subsidiary Laurus Bio just finished a big expansion plan, it is anticipated that the company would see tremendous growth. It wants to increase Laurus Bio’s fermentation capacity by one million liters, which will be operational in 2023–2024 and have fuel growth in 2024–2025.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Cadila Healthcare Limited.
To begin, the pharmaceutical industry has shown immense growth over the years. Every pharma product goes through a series of stringent research, innovation, and regulation to deliver good quality drugs and medicines, after all, it is a matter of health.
One cannot even imagine a life without medicines and drugs. Today, we have so many medicines for flu and fever and other key discoveries related to prolonged illnesses as well.
Previously known as Cadila Healthcare Limited, Zydus Lifesciences Limited, an Indian multinational pharma company is primarily engaged in the manufacture of generic drugs. Founded in 1952 by Ramanbhai Patel, Zydus Lifesciences Limited has its corporate office in Ahmedabad (Gujarat), India.
Zydus Lifesciences is thoroughly engaged in producing formulations for active pharmaceutical ingredients, animal healthcare products, and wellness products. Furthermore, it creates and produces a wide variety of medications, diagnostics, herbal remedies, cosmetics items, and other over-the-counter (OTC) goods.
It is a leading Indian pharmaceutical business and a fully integrated, international healthcare provider. It has excellent capabilities across the whole pharmaceutical value chain and extensive domain understanding in the field of healthcare.
Zydus Lifesciences has its headquarters in Ahmedabad, India. It has the fourth-place position in the country’s pharmaceutical market, with production and research facilities dispersed over five states: Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. Globally, the group is well-represented in the highly visible markets of Latin America and South Africa as well as the regulated markets of the US and Europe (France and Spain). It is also well-established in 25 other developing markets throughout the world.
Zydus is a pharmaceutical business focused on research, along with 1300 researchers operating across 19 facilities on its innovation program, which is developing distinctive medications for the future. NCEs, vaccines, biosimilars, and specialized technologies are just a few of the ideas and concepts the group is studying while also constantly inventing.
Zydus Lifesciences has four major subsidiaries, these are:
Zydus Wellness Limited (ZWL) – The company re-launched the Complan brand with improved taste and packaging design
Lipaglyn Saroglitazar – A new drug in treating Diabetic Dyslipidemia
Exemptia Adalimumab – It is ananti-inflammatory drug
ZyCoV-D – The Drugs Controller General of India (DCGI), Government of India, granted the company authorization to undertake human trials of the developing COVID-19 vaccine dubbed ZyCoV-D in 2020.
Zydus Lifesciences’ CSR & EHS initiatives
The company’s aims and business operations include a commitment to environmental conservation, employee health, and safety. It has a dedicated Environment, Health, and Safety (EHS) cell that works with all stakeholders across functions to create a distinct EHS culture to achieve environmental, health, and safety excellence across all units.
Zydus Shrishti, the company’s CSR initiative, focuses on health, education, and research. The Zydus Foundation has established the Zydus Medical College and Hospital in Dahod. The hospital provides free care for patients, including OPD, hospitalization, all investigations, operations, anesthesia, oral drugs, injectables, and meals.
It has also set up a medical college in Dahod, which is a self-financed brownfield medical college project established under the Government of Gujarat’s Public Private Partnership (PPP) model.
Zydus has conducted over 3000 awareness sessions on the prevention of various disease conditions.
Zydus Lifesciences Limited – Industry Details
The pharmaceutical business is massive, with a global market of more than US$ 1.4 trillion. Moreover, COVID-19 increased worldwide drug consumption, owing to fast immunization and the development of novel treatment options. Global COVID-19 investment is estimated to approach $80 billion in 2021, with total spending exceeding $251 billion through 2026.
Nevertheless, India is a prominent and expanding player in the global medicines market. It is no surprise that India is the world’s largest provider of generic pharmaceuticals, accounting for 20% of global supply by volume and fulfilling over 60% of global immunization demand.
Zydus Lifesciences Limited – Founder and Team
Zydus Lifesciences Limited was founded by Indian chemist, Ramanbhai B. Patel in 1952.
Ramanbhai B. Patel
Ramanbhai Patel was born in South Gujarat in Kathor on 19 August 1925. Before working as an instructor there, he was a student of chemistry at Gujarat University’s L.M. College of Pharmacy. He founded Cadila Laboratories with his school friend Indravadan Modi in 1951. However, due to some disagreements, the business split in two in 1995; Raman Patel established Cadila Healthcare, and Modi established Cadila Pharmaceuticals. The 2019 Gandhi Mandela Peace Award was hosted by Ramanbhai Patel. Ramanbhai Patel passed away on 19 September 2001 in Mumbai, India.
Pankaj R. Patel
Pankaj Ramanbhai Patel is a multimillionaire businessman. He was born in 1953 and is the Chairman of Cadila Healthcare, now known as Zydus Lifesciences. He has a Bachelor of Arts in Science and Law from the University of Mumbai, and a Bachelor of Pharmacy and Master of Pharmacy degrees from Gujarat University. Pankaj Patel joined Cadila Healthcare, which was established by his father, Ramanbhai Patel in 1952 to produce vitamins, after receiving his degree.
Pankaj Patel serves as the chairman of the boards of governors of the Indian Institute of Science Education and Research in Kolkata and the Indian Institute of Technology in Bhubaneswar. He is also a member of the boards of governors and the chairman of the finance committee of the Indian Institute of Management in Ahmedabad, the chairman of IIM Udaipur, the chairman of the school of life sciences at Ahmedabad University, and the board of management of the Ahmedabad University.
In honor of the expansion of Cadila under his direction, Pankaj Patel was named the “Best Pharma Man of the Year of 2003” by the Foundation of Indian Industry and Economists. Pankaj Patel is married to Priti Patel and has two children.
Zydus Lifesciences Limited – Startup Story
The story begins when Ramanbhai Patel and his business partner Indravadan Modi established Cadila in 1952. Over the subsequent forty years, it developed into a well-known pharmaceutical corporation.
In those years, Isopar, a combination of the anti-tuberculosis medications isoniazid and para-aminosalicylic acid, was produced in 1957, and Neuroxin-12, a single-vial mixture of vitamins B1, B6, and B12, was produced in 1959.
Things got changed when the Modi and Patel families separated in 1995. The Modi family’s portion was transferred to a new business called Cadila Pharmaceuticals Ltd., while Cadila Healthcare Ltd. became the holding company for the Patel family. In 2000, Cadila Healthcare under the stock number 532321 had its first public offering on the Bombay Stock Exchange.
Under the trade name Exemptia, Zydus Lifesciences introduced the first adalimumab biosimilar in 2014 at a price that was one-fifth that of the original. Saroglitazar, a medicine based on research, has also been made available by the company under the trade name “Lipaglyn” for the treatment of diabetic dyslipidemia. Zydus introduced SoviHep, the first sofosbuvir brand, to India in 2015.
2019 saw the recall of injectable ketorolac tromethamine produced by Zydus (Cadila Healthcare) owing to microbial development.
Zydus Lifesciences Limited replaces Cadila Healthcare Limited as the company name in 2022.
Zydus Lifesciences Limited – Mission and Vision
The mission statement of Zydus is, “To unlock new possibilities in life sciences through quality healthcare solutions that impact lives.”
Zydus’s vision reads, “To be a global life sciences company transforming lives through pathbreaking discoveries.”
The company aims to give people the independence they need to lead healthier, and more contented lives.
Zydus Lifesciences Limited – Name, Tagline, Logo
Before Zydus Lifesciences, the company was popularly known as Cadila Healthcare Limited. The tagline of Zydus Lifesciences is, “Dedicated to Life”
Its new logo depicts a stylized representation of two hearts with the word “Us” in the middle. Zydus’s logo colors are vivid and deeply symbolic highlighting the fact that everything the company does is for them which is “Us”, which includes the company’s diverse group of stakeholders, including staff members, patients, carers, partners, and customers.
The teal color in the logo expresses the company’s dynamism and purple symbolizes its purposefulness and dedication.
Zydus Lifesciences Limited – Business Model
As mentioned earlier, Zydus is mainly involved in the manufacturing of generic drugs, APIs, Animal healthcare products, and other OTC goods. The company has a global manufacturing footprint of 35 facilities that adhere to strong regulatory compliance requirements and have the capacity to manufacture multiple dosage forms at scale, allowing it to provide clients globally with cost-effective and high-quality pharmaceutical goods. About 7-8% of its annual revenues are invested in research and development.
Here’s taking a look at Zydus’s main business operations:
Zydus Research Centre (ZRC) is the company’s specialized unit in charge of driving its NCE research efforts. Cardiometabolic illnesses, inflammation, fibrosis, and infectious diseases are among ZRC’s NCE research priorities.
The Company’s vaccine development projects are housed in the Vaccines Technology Centre (VTC) in Ahmedabad. VTC has been working on vaccines for basic vaccination programs such as Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza, and Typhoid fever, as well as new vaccines such as Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, and Japanese Encephalitis.
Specialty and Complex Generics. The Company’s Specialty portfolio is focused on offering value-added therapies that meet unmet requirements while also providing patients and providers with a viable economic opportunity.
The company has one of the most complete and diversified biological product portfolios. The portfolio includes therapeutic fields like oncology, autoimmune illness, nephrology, ophthalmology, and other fields, including rheumatology, inflammation, hepatology, infectious illness, etc.
The group’s generic pharmaceutical development R&D operations are carried out in three Pharmaceutical Technology Centres (PTC) in Ahmedabad, India. These Centers provide formulations for worldwide markets, with a focus on specialty dosage forms and the development of skills on multiple technological platforms.
Zydus’s India Business
The company’s domestic’s business is divided into three major business segments; specialty business, chronic business, and mass business. It was the fastest growing company in India in the oncology sector while maintaining a leadership position in the super specialty of nephrology. To prevent and treat a variety of diseases in the fields of oncology, hepatology, nephrology, rheumatology, ophthalmology, and bone health, Zydus Biologics, a super-specialty centric business entity of Zydus Lifesciences Ltd., manufactures and commercializes both small molecule, biological drugs, and vaccines. It has launched around 37 new products including line extensions, out of which 13 were first in the domestic market.
Domestic sales increased by 7% to Rs 19,788 million, with a 160% increase in net profit to Rs 3,089 million. (FY2021-2022)
Zydus’s USA Business
Zydus Lifesciences has been ranked 5th among US generic companies based on prescriptions. The company’s business involved the launch of 14 products during 2021-2022. Despite growing competition and pricing pressure, the company tends to gain total volume and maintained a top three ranking in around 60% of product families. In terms of volume, the company led in around 20% of the product groups. Sales made in the USA were reported to be Rs 58,138 million.
Zydus’s Asia, Africa, and Latin America Business
With 30 products classified as leaders in their respective molecular categories, the company reclaimed first place in Sri Lanka with a 7.4% market share. Zydus’s international business sales increased by 17% to Rs 11,921 million.
Zydus Lifesciences Limited – Revenue Model
The total revenue made by Zydus Lifesciences is reported to be Rs 15,139 crores. It claims that its total income from operations grew by 6% to Rs 152.7 crores from Rs 144 crores last year (2020-2021). There was a 21% Y-o-Y increase in the branded business (excluding sales of COVID-related products, the generics portfolio, and sold brands). Twelve of the company’s products are among India’s top 300 pharmaceutical brands. During 2021-2022, eight brands had sales above Rs 100 crores, 22 brands had sales between Rs 50 and Rs 100 crores, and 36 brands had sales between Rs 25 and Rs 50 crores.
Zydus Lifesciences Limited – Funding and Investors
Zydus Lifesciences Ltd. has three joint ventures. Some of these are;
Zydus Takeda Healthcare Pvt. Ltd. – It is a 50:50 joint venture between the Company and Takeda Pharmaceuticals Co. Ltd., (Japan)
Zydus Hospira Oncology Pvt. Ltd – It is a 50:50 contract manufacturing joint venture between Zydus and Hospira Inc., USA (now part of Pfizer group)
Bayer Zydus Pharma Pvt. Ltd. – Bayer (South East Asia) Pte. Ltd. (wholly owned subsidiary of Bayer AG, Germany) and Zydus Lifesciences Limited have a 75:25 marketing joint venture.
Zydus Lifesciences Limited – Mergers and Acquisitions
Zydus Lifesciences has raised a total of $7 million in investment. It was funded by Baring Private Equity India in a Post-IPO Equity round.
Zydus Lifesciences Limited – Mergers and Acquisitions
Till now, Zydus has purchased three businesses. Windlass Biotech was their most recent purchase as of August 13, 2018. For Rs 160 crores, they bought Windlass Biotech. Windlass Biotech is Gurgaon-based healthcare that engages in pharmaceutical drug development and contract research services. Here is the list of acquisitions made by Zydus:
Date
Acquiree name
Amount
August 13, 2018
Windlass Biotech
Rs 160 crores
January 19, 2017
Sentynl Therapeutics, Inc.
–
December 22, 2011
Biochem Pharmaceuticals
–
Zydus Lifesciences Limited – Advertisements and Social Media Campaigns
Recently, Zydus Lifesciences re-launched the popular energy drink of children ‘Complan’ with improved taste. It was accompanied by the tagline “Ummeedo se aage badhne ka plan” campaign, which communicates the crucial advantages of the brand. The advertisement focuses that if children consume Complan it will not only improve their growth but also their memory and attention.
Zydus Lifesciences Limited – Awards and Achievements
The list of awards and achievements won by Zydus Lifesciences are;
Zydus received the IDMA Aptar innovation of the year award and Corporate citizen award (2022)
Pharma Company Of The Year Award by ETHealthworld India Pharmaworld Awards 2022
Zydus achieved the HR Asia award in the category of Best Companies to work in Asia 2021 in the India region.
Zydus was declared the most Innovative Pharmaceutical Company by Thomson Reuters.
Zydus received the 7th India Pharma and India Medical Device award by the Government of India (2021-2022)
Zydus was recognized for Excellence In CSR at ETHealthworld India Pharmaworld Awards 2022.
Zydus Lifesciences was recognized as India’s Best Workplace in Biotechnology and Pharmaceuticals by Great place to work 2022.
Zydus Lifesciences Limited – Competitors
The list of top competitors of Zydus Lifesciences is:
Zydus Lifesciences Ltd. recently announced the acquisition of up to an 11.86% stake in AMP Energy Green Nine. The company is also planning to launch Lenalidomide capsules, which is a cancer treatment medication that works in slowing or preventing cancer cell proliferation in the USA market.
FAQs
Who is the CEO of Zydus?
Tarun G Arora is the CEO of Zydus.
Is Zydus a public company?
Yes, Zydus is a public company.
Where is the headquarter of Zydus Lifesciences?
The headquarter of Zydus Lifesciences is in Ahemdabad.
What is the rank of Zydus in India?
In Ind, Zydus ranks as the 4th biggest pharma company.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Sun Pharma.
It was in the mid-1800s when pharma industries started by distributing botanical drugs such as morphine. Gradually, with applied research studies, the industry started picking up pace, which resulted in the development of new drugs.
The post-world wars gave birth to a wide variety of new antibacterial drugs. Ever since pharmaceutical manufacturing companies have been significant in creating potential drugs, that many of us are familiar with in our day-to-day lives.
In the 1980s, a lot of pharmaceutical companies started to hit up the market, and one of them was Sun Pharma. With their continuous efforts and innovations,Sun Pharmabecame the largest pharmaceutical company in India and the fourth-largest speciality generic pharmaceutical company in the world.
This article covers all the suitable information related to Sun Pharma, like its success story, its founders, its key products and services, its business and revenue model, and more.
Sun Pharma, founded in 1983, is a global pharmaceutical firm that develops and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in over 100 countries worldwide with around 40 manufacturing facilities. Its R&D centres throughout the world, as well as a multicultural staff of over 50 nationalities. Countries like Brazil, Mexico, Russia, Romania, and South Africa are some of its key emerging markets. The company likes to promote excellence via strategic innovation, which is supported by strong R&D capabilities that include about 2,000 scientists and R&D spending of more than 7-8% of annual revenues.
Absorica, Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budesonide, and Carvedilol are among its API products. Psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dentistry, and nutrition are among the therapeutic categories served by Sun Pharma. The company claims to have more than 37,000 people employed across its global offices.
Sun Pharma consists of having a diversified speciality and generics portfolio that further consists of nearly 2000 high-quality compounds, which is available in a variety of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.
Sun Pharma was placed on the stock exchange in 1994, with an issuance that was 55 times oversubscribed. The original family still owns the bulk of the corporation.
Sun Pharma – Industry
One of the biggest industries in the world is the pharmaceutical industry. Moreover, as per records, the Indian Pharmaceutical industry ranks third in the world in terms of pharmaceutical production by volume.
The pharma market has seen tremendous growth over the past few years, especially after the pandemic. The total revenue of the global pharmaceutical market was valued at $1.27 trillion in 2020.
Dilip Shanghvi is the founder and MD of Sun Pharmaceuticals Industries Ltd. He was born in the Indian state of Gujarat to Shantilal Shanghvi and Kumud Shanghvi in the tiny village of Amreli. Dilip Shanghvi’s career took a turn when he began by assisting his father at his business, a wholesale dealership of pharmaceuticals, primarily generic drugs in Kolkata. But later, he considered producing his pharmaceuticals rather than selling those manufactured by others. Today, he is one of the country’s richest people with a net worth of $14.3 billion. In 2016, the Indian government bestowed upon him the civilian honor of Padma Shri. After a year, India Today magazine rated him eighth on its list of the country’s most powerful persons.
Dilip Shanghvi was nominated to the Reserve Bank of India’s 21-member central board committee in January 2018. He is also the head of the IIT Bombay board of governors. There’s a book on him, which is the first and only biography of Dilip Shanghvi, ‘The Reluctant Billionaire’ written by journalist Soma Das. The book was nominated for Tata Literature Award in the Best Business Book category in 2019. Dilip’s wife’s name is Vibha Shanghvi. The couple has two children, one daughter, and one son.
Israel Makov
Israel Makov was the Non-Executive Chairman of the Company. He recently retired from the company in August 2022. Before becoming a part of Sun Pharma, Israel Makov served as the President & CEO of Teva Pharmaceutical Industries Ltd from 2002 to 2007. He had directed a variety of enterprises in diverse areas before joining Teva. Among them was Interpharm, his first biotech firm, which he started and later took public in the United States.
Israel graduated from the Hebrew University in Jerusalem with a B.Sc. in Agriculture and an M.Sc. in Economics. He is a member of the Weizmann Institute of Science’s Executive Board and Management Committee, the Technion’s Board of Governors, and a Director of Yeda Research and Development Company Ltd. Israel Makov is also the Chairman of Israel’s leading theatre, the Gesher Theatre.
Under Israel’s leadership, the company transformed from a $1.7 billion organization operating in India and USA to the world’s fourth-largest specialty generic pharmaceutical company operating in more than 100 markets.
Sun Pharma – Startup Story
The startup story of Sun Pharma started in Vapi, Gujarat, which is a few hours’ drive from Mumbai. Dilip Shanghvi set up his first manufacturing plant there with a capital of Rs 10,000. In the initial days, the pharma company manufactured only psychiatry drugs but it soon scaled up its business. By 1997, the company’s business was a hit and was able to make its first acquisition by acquiring Caraco Pharma, an American company.
At present, Sun Pharma is the market leader in fields like diabetology, cardiology, urology, gastroenterology, ortho, dermatology, vitamins, minerals, and nutrients, with nine other distinct specialties of specialists.
Sun Pharma – Mission and Vision
Sun Pharma’s vision is, “Reaching People And Touching Lives Globally As A Leading Provider Of Valued Medicines”
The firm wants to offer medicines that are of prime quality and affordable to most people.
The company follows its idealogy based on five core values:
Reliability
Trust
Quality
Innovation
Consistency
Sun Pharma – Name, Tagline, and Logo
Sun Pharma Logo
The name Sun Pharma is based on the idealogy of the sun.
The tagline of Sun Pharma reads, “Science is at the heart of Sun Pharma” The logo of the company is a symbol that is similar to the shape of the sun in bold orange and light orange colour combinations.
Sun Pharma – Business Model
Sun Pharma operates its business by manufacturing and selling pharmaceutical formulations and active pharmaceutical ingredients (APIs).
Sun Pharma produces an extensive variety of therapeutic segments, specialty medicines, generic medications, and over-the-counter (OTC)/consumer healthcare products with its brand names like Faringosept for sore throat treatment, Revital (multivitamins), Volini for topical analgesics. It further includes other categories of brands such as Coldact & Flustat, Brustan, Painamol & Paduden, Gestid, Aspenter, Aspacardin, Chericof, and Nudrate & Fortifikat.
Sun Pharma’s business operations also involve a wide range of Anti Retro Viral Medications (ARV), which are all qualified by WHO. The supplies ARVs to diverse National AIDS treatment programs in Africa. The company wants to contribute significantly to fighting HIV/AIDS by producing first-line and second-line Highly Active Antiretroviral Therapy (HAART). Its business operations are present in almost 100 countries.
Sun Pharma CSR Activities
Sun Pharma also focuses on serving and helping society. There are a lot of underprivileged communities in India, and Sun Pharma with its CSR activities aims to serve the community in three primary areas: health, education, safe drinking water, and sanitation.
The CST mission of Sun Pharma is, “To leverage our people, expertise, and networks to address the needs of the communities that we serve and thereby catalyze overall development.”
Sun Pharma has the following CSR projects:
Malaria Elimination Demonstration Project (MEDP)
A partnership between the Indian Council of Medical Research (ICMR), the Government of Madhya Pradesh (GoMP), and the Foundation for Disease Elimination and Control of India (FDEC India) is a non-profit enterprise with a primary focus on reducing malaria cases in over 200 villages of the Mandla district.
Mobile Healthcare Units (MHUs)
MHUs deliver primary healthcare services to more than 650,000 people who live near Sun Pharma’s manufacturing sites and other establishments. It offers services like health-check ups and free medicines.
Model School Development
This project is implemented to empower students coming from rural areas to give them the basic right to education and other development opportunities.
Safe Drinking Water and Sanitation
This project by Sun Pharma aims to provide access to hygienic and clean drinking water and good-quality washrooms and toilets in various regions in villages.
Sun Pharma Science Foundation
The Sun Pharma Science Foundation is a recognized non-profit organization under the Societies Act. This foundation gives motivation and encouragement to those who excel in the medical and pharmaceuticals line.
Environmental, Health & Safety (EHS) programs
The program of EHS by Sun Pharma aims an establishment of a safe and healthy workplace as well as a clean environment for all workers and the communities it serves.
Sun Pharms CSR
Sun Pharma’s Covid-19 initiatives
The company was deeply engaged in providing Covid-19-specific medicines to help curb the virus and the community in general. Some of the initiatives launched by Sun Pharma are:
‘Sunkalp’, is a special initiative by Sun Pharma for the welfare of doctors, their families, and the community.
Teamed up with MSD, popularly known as Merck in the United States and Canada. MSD gave special rights to Sun Pharma to manufacture, market, and distribute Molnupiravir in India.
Sun Pharma donated a sum of Rs 250 million of Hydroxychloroquine (HCQS), Azithromycin, other related drugs, and hand sanitizers in India. It has also made other donations related to Covid-19 medicines and PPEs within international boundaries.
Set up manufacturing units just to produce Covid-19-specific medicines such as Vecuronium (anaesthesia), Midazolam (anxiety), Ivermectin (antiviral), Azithromycin (antibiotic), and HCQS.
Sun Pharma launched FluGuard (Favipiravir 200 mg) in 2020. The tablet is set at an economical price of Rs 35 to treat mild to moderate Covid cases in India.
Sun Pharma – Revenue Model
It is reported that over 72% of Sun Pharma sales are from markets outside India, predominantly in the United States. Furthermore, the USA is the largest market area for Sun Pharma from where the company gets 30% of its total revenue from the USA markets. The revenue comes from its 44 global locations in India, the USA, Africa, Asia, Australia, and Europe.
Sun Pharma – Revenue Growth
Sun Pharma made a revenue of Rs 39,576 crores, which is equal to $5.0 billion in 2022. It had a net income of Rs 3,405 crores. It is reported that after deducting extraordinary items of Rs 3,935.7 crore and exceptional tax gain of Rs 76.4 crore, the adjusted net profit for the quarter was Rs 1,582.1 crore, which is up 18% year on year.
The contribution of Sun Pharma’s global specialty business has nearly doubled from 7% of consolidated revenues in FY18 to about 13% in FY22. Moreover, the company claims that in FY22, India formulation sales were at Rs 127 Billion, up 23%, and accounted for about 33% of overall revenues. Excluding the contribution of COVID products, the underlying business of Sun Pharma performed well, with about 20% growth over the previous year.
Sun Pharma – Investments
Sun Pharma has invested in four companies. Their investment is in Zenotech Laboratories, a pharmaceuticals company in India,which raised ₹53.2 million on March 21, 2022. Following is the list of investments by Sun Pharma:
Date
Company Name
Amount Invested
March 21, 2022
Zenotech Laboratories
₹53.2 million
September 10, 2018
Tarsier Pharma
$3 million
August 8, 2017
Krystal Biotech
$7 million
January 4, 2017
scPharmaceuticals
$45.6 million
Sun Pharma – Mergers and Acquisitions
Sun Pharma has bought seven companies. POLA-Pharma was their most recent purchase, which occurred on November 27, 2018. The acquisitions are:
Date
Acquiree name
Amount
November 27, 2018
POLA-Pharma
–
July 28, 2017
Zenotech Laboratories
₹855 million
November 23, 2016
OJSC Biosintez
$24 million
October 27, 2016
Ocular Technologies Sarl
$40 million
September 15, 2015
InSite Vision
$48 million
April 6, 2014
Ranbaxy Laboratories
$3.2 billion
November 9, 2012
DUSA Pharmaceuticals
$230 million
Sun Pharma – Advertisements and Social Media Campaigns
With a strong social media presence, Sun Pharma has launched multiple campaigns related to its brands. In 2021, Sun Pharma ran an advertisement about their brand Revital, titled: REVITAL H 21 Days Challenge with the #rahocharged. The advertisement features Bollywood Actor Akshay Kumar promoting their multivitamin supplement product Revital. The ad by Sun Pharma promotes taking up the 21 days challenge by having revital to feel energized in just 21 days.
During the pandemic, Sun Pharma released a thank you campaign titled: Sun Family Stands United With All Corona Warriors to extend their support to every frontier to stay united and fight against the Covid-19 pandemic.
Sun Pharma – Awards and Achievements
Some of the awards and milestones of Sun Pharma in recent years are:
2022
Sun Pharma was recognized as the No. 1 generic pharmaceutical company by patient groups in the annual PatientView ‘Corporate Reputation of Pharma’ survey 2021
Acquired the Uractiv portfolio from Fiterman Pharma in Romania
2021
Sun Pharma bagged the DIANA (Distribution Industry Award for Notable Achievements in Healthcare) award for ‘Best New Product Introduction/Promotion’
Sun Pharma received the Golden Peacock Award for Corporate Social Responsibility, 2020
Received the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards.
Launched a specialty dermatology product called WINLEVI in the U.S. for topical treatment of Acne Vulgaris
2020
Sun Pharma was listed among the Forbes World’s Best Employers 2020
2019
Sun Pharma was ranked No. 1 in the pharma sector and No. 16 overall in the BW Businessworld list of India’s Most Respected Companies
Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence
Sun Pharma Foundation for Disease Elimination and Control of India received the Mahatma Award for Social Good in 2019
2018
Sun Pharma received the Best CSR Practices Award from The Economic Times
Sun Pharma was listed among the Forbes World’s Best Employers
Sun Pharma – Competitors
Here is the list of top competitors of Sun Pharma:
Sun Pharma has mentioned in its future plans that its top focus area for FY23 is to ramp up its global specialty business. It also plans to have a business expansion that is both sustainable and lucrative. The company is planning to have a proper maintaining supply chain continuity while focusing on inventory management along with increasing investments in IT to allow business and digital transformation and to improve overall return ratios.
FAQs
Is Sun Pharma the top most Indian pharma company?
Yes, Sun Pharma is the top pharma company in India in terms of market capitalization.
Which is the most popular product by Sun Pharma?
Revital is among one of the most popular products by Sun Pharma.
Who is the CEO of Sun Pharma?
Kal Sundaram is the current CEO of Sun Pharma.
Where is the head office of Sun Pharma?
The head office of Sun Pharma is in Goregaon, Mumbai.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Biocon Limited.
The healthcare marketplace is drastically evolving with many therapeutic solutions. Biopharmaceutical is one such discovery in the healthcare sector that is treated as one of the most significant achievements in modern science and technology. The biopharmaceutical industry is different from pharmaceutical startups in terms of the manufacturing process.
Biopharmaceutical products or medicines are manufactured in or, extracted from living organisms or biological sources, unlike pharmaceuticals, which are manufactured using chemical substances.
Known as an international pioneer, Biocon Limited, is an Indian biopharmaceutical firm founded by Kiran Mazumdar-Shaw in 1978. The company is based in Bangalore, India, and produces generic active pharmaceutical ingredients (APIs) that are distributed in over 120 countries worldwide.
Founded in 1973, Biocon Limited produces both new biologics and biosimilar insulins and antibodies, and generic APIs across the globe covering more than 120 countries, the major being the USA and Europe markets. The company consists of a talented and dedicated workforce of 13,500 employees.
For 40 years, Biocon has been consistently creating a culture of continuous innovation with four global businesses such as – generics, biosimilars, research services, and novel biologics. Its research and development are focused on prevention, relief, treatment, and medicines to enhance the lives of millions of patients. They believe in offering affordable quality medicines for many people. It strives to give reasonable access to a specialty portfolio of medications to everyone, everywhere.
As a global brand, Biocon is leveraging economies of scale by consistently investing in the development of new treatments for diabetes, cancer, and immunology. Biocon’s subsidiaries are –
Biocon Biologics and Syngene International Limited (Syngene).
Biocon Limited – Industry details
The Covid-19 impact has led to the growth of the Biopharmaceuticals industry in recent times. As per records, the global biopharma industry market growth is expected to reach $26.49 billion in 2028. This growth will see a CAGR of 12.6% during the period from 2021 to 2028.
Biocon Limited – Founder and Team
Biocon Limited is founded by Indian billionaire entrepreneur, Kiran Mazumdar-Shaw in 1978.
Kiran Mazumdar-Shaw – Founder of Biocon
Kiran Mazumdar-Shaw
Awarded the EY World Entrepreneur Of The Year 2020 and the first woman to head the board of governors of the Indian Institute of Management Bangalore, Kiran Mazumdar-Shaw is an inspiration for many women. She was born to Gujarati parents on March 23, 1953, in Bangalore, Karnataka. Rasendra Mazumdar, her father, was the head brewmaster of United Breweries.
Kiran Mazumdar-Shaw attended Mount Carmel Institution in Bangalore, a women’s college affiliated with Bangalore University, where she studied biology and zoology, earning a bachelor’s degree in 1973. Listening to her father’s advice, Kiran went to Ballarat College, Melbourne University in Australia to study malting and brewing attaining a master’s degree in brewing in 1975.
Before Biocon, Kiran was a trainee brewer at Carlton and United Breweries in Melbourne, as well as a trainee maltster at Barrett Brothers and Burston. Between 1975 and 1977, she also served as a technical consultant at Jupiter Breweries Limited in Calcutta and as a technical manager at Standard Maltings Corporation in Baroda.
Kiran Mazumdar-Shaw has done many philanthropic activities such as the Biocon Foundation. Through this foundation, she has supported Arogya Raksha Yojana (Disease Protection Program/Health Help) and numerous other health and education programs. She has also supported the Bangalore Agenda Task Force, to improve the city’s infrastructure and standard of living.
Kiran Mazumdar-Shaw is the Chairperson of Biocon Limited. In her lifetime, she is the recipient of many prestigious awards. Just to name a few, she was conferred the prestigious Quality Ratna Award for the year 2020 by the Confederation of Indian Industry (CII), she was elected as a Fellow of the Royal Society of Edinburgh (RSE), Scotland’s National Academy, she received the Othmer Gold Medal in 2014 for exceptional contributions to the progress of science and chemistry. Kiran also received the Padma Shri in 1989 and the Padma Bhushan in 2005 from the government of India. Not to forget, she was ranked #68 on the Forbes list of the World’s 100 Most Powerful Women in 2020.
Kiran is married to John Shaw. He is a Scotsman and Indophile who was Chairman and Managing Director of a renowned textiles MNC Madura Coats before joining Biocon in 1999 and serving as Vice-Chairman and Non-Executive Director of Biocon for almost 22 years before retiring recently in July 2021.
Dr. Arun Chandavarkar
Dr. Arun Chandavarkar is the Managing Director of Biocon Biologics Limited. He formerly served as the CEO and Joint Managing Director of Biocon Ltd. from April 2014 until November 2019, when he left after nearly three decades with the company. Before becoming CEO, he was the Chief Operating Officer of Biocon.
Dr. Chandavarkar earned a bachelor’s degree in chemical engineering from the Indian Institute of Technology (IIT) in Mumbai and a doctorate in biochemical engineering from MIT in Cambridge, Massachusetts. Under his management, the company has made significant investments in cutting-edge R&D and efficient, compliant operations, resulting in a distinct and differentiated product portfolio that includes fermentation-derived complex generics, biosimilars, and novel biologics aimed at a global patient population. For the 2016-17 fiscal year, Dr. Chandavarkar chaired the Confederation of Indian Industry’s (CII) National Committee on Biotechnology.
Siddharth Mittal
Siddharth Mittal is the CEO and Managing Director of Biocon Ltd. He has more than 20 years of comprehensive international expertise in strategic finance and accounting, mergers and acquisitions, taxation, and general management.
Siddharth Mittal was formerly Vice-President, Finance, and Corporate Controller at Symphony Teleca, a renowned US-based international IT business. He began his career in Bengaluru with the audit division of S.R. Batliboi & Co. (the Indian branch of Ernst & Young). He then worked for the US division of Xchanging Plc, an FTSE-listed firm located in London that specializes in business processing, technology, and procurement services.
Siddharth graduated from the Symbiosis College of Arts and Commerce in Pune with a Bachelor of Commerce. He is a Chartered Accountant from the Institute of Chartered Accountants of India and a Colorado Certified Public Accountant. Presently, he is also Co-Chairman of the CII Southern Regional Task Force on Pharmaceuticals and Co-Chairman of the CII Southern Regional Healthcare & Life Sciences 2020 – 21.
Biocon Limited – Startup Story
The story of Biocon started in 1978. It began as a joint venture with an Irish biotech business to develop and export enzymes for the brewing industry internationally. The company then gradually created a solid-state fermentation technique to manufacture innovative bio-enzymes for worldwide clients in the food and pharmaceutical sectors.
Unilever Plc purchased its Irish partners in 1989 and produced Biocon India as a member of the Unilever system, which allowed the company to quickly professionalize by adopting worldwide best practices.
In the 1990s, Syngene was established as a ‘pure play’ research services firm catering to the worldwide pharmaceutical industry’s R&D needs. Biocon moved beyond insulins to create monoclonal antibodies.
During its journey, Biocon found that most of the developing world couldn’t afford all the advanced therapeutic solutions. To support its purpose, Biocon raised capital through an IPO in 2004 and sold its enzymes business in 2007. Through constant research and developments, Biocon acquired a worldwide reputation as a genuine biosimilars player through a series of groundbreaking milestones, beginning with the approval of the world’s first bTrastuzumab in India in 2014 and the Japanese approval of bGlargine in 2016. It was the first in the world to receive approval in the United States for bTrastuzumab in 2017 and bPegfilgrastim in 2018.
Biocon’s investments on a global scale helped the company rank among the world’s top 15 biomanufacturing companies.
Currently, Biocon has emerged as one of the leading global biopharmaceutical companies with consolidated revenues of $1.1 billion (Rs 8,396.70 crores) and a more than 15,000 strong workforce.
Biocon Limited – Mission and Vision
Biocon’s vision statement reads, “To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners, and healthcare systems across the globe.”
The company aims to deliver high-quality and reasonable healthcare products by prioritizing patients, focusing on science, and sustainable growth.
The mission of Biocon is, “To be an integrated biotechnology enterprise of global distinction”
Biocon Limited – Name, Tagline, Logo
The logo of Biocon can be seen to have a similar appearance to human DNA.
The overall tagline of Biocon as a company is, “Hope.saves lives.”
Biocon also has taglines for each of its subordinates:
Biocon Academy’s tagline is, “Adding Value, Enhancing Skills”
Biocon Limited – Business & Revenue Model
The business model of Biocon can be said to have five global business verticals – Generics, Biosimilars, Research Services, and New biologics, Research and development, and manufacturing of revolutionary biopharmaceutical medications. This developing paradigm is nicely linked with its business objective of offering inexpensive innovation. The company’s integrated business strategy encompasses the whole therapeutic value chain, from pre-clinical discovery to clinical development and beyond.
Biocon has three main business divisions that are its strength and backbone. This consists of – Syngene, Clingene, and Biocon, which are engaged in preclinical, clinical, and commercialization activities, respectively. Its business operations also involve the manufacturing of therapeutic areas such as Oncology, Diabetes, and Immunology.
Biocon’s business also includes developing enormous brand equity with physicians and patients by expanding its footprint into specialist sectors through which it earns its revenue. It has also produced medicines for Covid-19 such as – Alzumab-L, Dynalix, RemWin, etc.
Biocon’s CSR Activities
The company has no space when it comes to serving society. With its motto, “Driving Sustainable Social Change”, the company aims to be devoted to bettering lives and strengthening marginalized communities for a brighter future. The CSR initiatives of Biocon can be divided into two categories:
Biocon Foundation – Through this, Biocon has emphasized many healthcare solutions, providing for the environment and people through programs that promote social and economic inclusion. The company has set up eLAJ Smart Clinic platforms, an Oral Cancer Screening program, did a Community Vaccination Drive, supplied oxygen concentrators, Intensive Care Unit (ICU) monitors, digital X-Ray machines, ultrasound machines, pulse oximeters, and other medical equipment to support the COVID care infrastructure at the Anekal General Hospital and a lot more other social initiatives.
Biocon Academy – In conjunction with JSS University, Mysuru, Biocon Academy, helps to establish an ecosystem for biotech-related skills in India. The programs offered by the academy aim to provide advanced learning and industrial competence to life science graduates and post-graduates through job-skills development, which is required to create a rewarding career in the Biotech sector.
It recently launched a new course in Global Regulatory Affairs. The Academy was established 8 years ago. Till now, more than 850 students have enrolled in the academy.
Biocon is involved in offering many sustainable activities to provide a rewarding workplace through the EHS management system and to improve ESG (Environmental, Social, and Governance).
Biocon Limited – Revenue & Growth
As per reports, Biocon’s consolidated revenues increased 14% year on year to Rs 83,967 million, led by Biosimilars and Research Services revenue increases of 24% and 19%, respectively. Furthermore, for the fiscal year, Biosimilars earned Rs 34,643 million, Generics earned Rs 23,409 million, and Research Services earned Rs 26,042 million.
The company also claimed that its EBITDA climbed 14% year on year to Rs 21,829 million, with a respectable margin of 26%. Core EBITDA for the year increased 18% to ‘26,690 million, representing a margin of 32% after adjusting for licensing, forex, gain on dilution in Bicara, mark-to-market loss on investments, and R&D expense. Biocon’s net profit was $6,484 million. Certain extraordinary events, mark-to-market losses on investments, and a gain on dilution in Bicara all influenced net profit. After adjusting for these things, Biocon managed to increase its Net Profit by 23% for the whole year.
Biocon has announced that in FY22, Biocon Biologics increased its sales by 24% over the previous year, to Rs 34,643 million, with interchangeable bGlargine achieving double-digit market share in the United States, as well as ongoing improvement in the market share of other major existing products.
Biocon also saw some growth in its business segments. Syngene increased its bio-manufacturing capacity by commissioning a cutting-edge microbial facility and expanding its mammalian plant. Besides this, Biocon Biologics successfully progressed two unpartnered antibody projects to the clinical stage, bUstekinumab and bDenosumab.
Biocon Limited – Funding and Investors
Biocon Biologics has raised $24.4 billion in funding over four rounds. Their most recent fundraising came on January 7, 2021, in the form of a Venture Series Unknown round. Biocon Biologics is supported by four investors. The most recent investors are ADQ and Goldman Sachs.
Date
Funding Round
Fund Amount
Investors
January 7, 2021
Venture Round
₹5.6 billion
ADQ
November 9, 2020
Private Equity Round
₹11.3 billion
Goldman Sachs
July 31, 2020
Private Equity Round
₹2.3 billion
Tata Capital
January 6, 2020
Private Equity Round
₹5.4 billion
True North
Biocon Limited – Mergers and Acquisitions
On February 28, 2021, Biocon Biologics bought Viatris Biosimilars. They paid $3.3 billion for Viatris Biosimilars. Viatris Biosimilars is a USA-based company that has primary areas of focus on Oncology, immunology, endocrinology, ophthalmology, and dermatology.
On September 16, 2021, Biocon Biologics Limited (“BBL”) entered into a merger cooperation agreement with Serum Institute Life Sciences Private Limited (“SILS”) and Covidshield Technologies Private Limited (“CTPL” or Transferor business), a fully owned subsidiary of SILS.
Biocon Limited – Advertisements and Social Media Campaigns
In 2020, Biocon Biologics released a series of videos with the #StoriesofHope. The campaign was launched on Women’s Day to share the stories of two women who have survived deadly diseases like cancer and breast cancer.
Biocon Limited – Awards and Achievements
Here’s is the list of Biocon’s awards and recognitions in the last few years:
2022
Biocon Group Communication Team moved up to no.6 among 30 Top Corporate Communication Team Nationally
Biocon Biologics was conferred with the prestigious Legal Era Award, “Pharmaceutical In-House Legal Team of the Year” for 2021-22
Biocon Biologics was conferred with the coveted ‘20th Annual Greentech Safety India Award 2021’ during the Safety India Summit.
2021
Biocon won the ‘UN Women India WEPs Awards – 2021’in the “Transparency and Reporting”
Biocon made it to the Top 15 Indian Companies in the Emerging Market Index of Dow Jones Sustainability Indices (DJSI)
Biocon Biologics received the ‘Unnatha Suraksha Puraskara’ on September 9, 2021, by the National Safety Council (NSC), Karnataka Chapter.
2020
Biocon was recognized at the ‘UN Women 2020 India WEPs Awards’ for promoting a Gender-Inclusive Workplace and Gender-Responsive Marketplace amidst COVID-19.
Biocon Limited was ranked among the Top 5 Global Biotech Employers for 2020
Biocon bagged the ‘Best Biotech Patents Award 2018-19’ by Indian Drug Manufacturing Association (IDMA)
2019
Biocon won 2 awards at the TISS-Leapvault CLO Summit: ‘Learning and Development Team of the Year’ and ‘Best Diversity & Inclusion Program’.
Biocon moved up to Rank No. 6 on Science Careers’ Top 20 Global Pharma and Biotech Employers List 2019.
Biocon showcased a strong presence at Bengaluru Tech Summit 2019 for which it won the ‘Best Exhibitor Award’.
2018
Biocon Foundation, the CSR arm of Biocon Ltd. and Syngene International Ltd., was felicitated with SABERA Awards in New Delhi.
Biocon was honored at Pharmexcil Outstanding Exports Award 2017-18 for outstanding contribution to India’s Pharmaceutical Exports during the year 2017-18.
Biocon was honored with the prestigious IDMA Corporate Citizen Award in 2017.
Right now, Biocon’s main focus is to expand its diverse product portfolio to become a trustworthy global brand. The company plans are gaining global leadership by utilizing its size and cost advantages. it is further building a company with flawless quality compliance, world-class ethics, and a strong corporate governance framework. Through digital and data analytics, it plans to get closer to patients and reach a broader patient base. It believes that its three business categories, Generics, Biosimilars, and Research Services, are all well positioned for future expansion.
FAQs
Who is the CEO of Biocon?
Siddharth Mittal is the CEO of Biocon Limited.
Who is the founder of Biocon?
Kiran Mazumdar Shaw is the founder and executive chairman of Biocon.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Aurobindo Pharma Limited.
It is hard to imagine if there were no pharmaceutical manufacturing companies. Then how would we have got the basic drugs like painkillers, antibiotics, anti-allergic tablets, or any other form of medication?
They say, health is wealth, and it is a fundamental need of every society. Thanks to these pharmaceutical manufacturing companies, they ensure that effective drugs can help enhance a person’s health and improve the overall quality of life.
Pharma company like Aurobindo Pharma Limited founded in 1986, is aiding society with their high-quality generic pharmaceuticals and APIs. Hyderabad’s HITEC City serves as the corporate headquarters for this worldwide pharmaceutical manufacturing company.
Know more about Aurobindo Pharma like its history and evolution, business model, revenue model, competitors, and much more mentioned in this article further.
The company mainly produces generic medications and active pharmaceutical ingredients (APIs). In 1992, Aurobindo Pharma went public, and in 1995, it listed its shares on the Indian stock exchanges. Aurobindo Pharma is the industry leader in semi-synthetic penicillins and also has a foothold in important therapeutic areas including gastroenterology, neurosciences, cardiovascular disease (CVS), antiretrovirals, and antibiotics. All of these products are marketed in over 150 countries. It is R&D-focused, which offers a variety of products, and has manufacturing sites spread across numerous nations.
The company also entered the lucrative speciality generic formulations area because of its affordable production capabilities and a few devoted clients. Presently, Aurobindo Pharma is ranked among the top ten pharmaceutical firms in India based on consolidated sales.
The company operates in-house R&D for the quick filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs), and Formulation Dossiers across the globe. Multiple facilities are approved by leading regulatory agencies, including USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO, and Brazil ANVISA. In addition, one of the top DMFs and ANDAs filers from India is Aurobindo Pharma.
Aurobindo Pharma – Industry
The Indian pharma industry has been seeing a tremendous growth rate in the last five years. As per reports, the Indian pharmaceutical market has been growing at a compound annual growth rate (CAGR) of more than 15% over the last five years. According to the Indian Economic Survey 2021, the growth is expected to be three times faster in the coming decade. The current market size for pharmaceuticals in India is $41 billion, which is expected to reach $65 billion by 2024 and $130 billion by 2030.
Aurobindo Pharma was founded by P.V. Ramprasad Reddy and K. Nityananda Reddy in 1986.
P.V. Ramprasad Reddy
P.V. Ramprasad Reddy – Founder and Non-Executive Director of Aurobindo Pharma
P.V. Ramprasad Reddy is an Indian businessman and one of the founders of Aurobindo Pharma. He holds a degree in Commerce. Mr Ramprasad Reddy is responsible for taking care of strategic planning for the company. He held senior positions in several pharmaceutical firms before founding Aurobindo Pharma in 1986.
Mr Ramprasad Reddy was placed No. 27 in India and No. 688 globally in the 2016 Forbes list of Indian billionaires, with a net worth of $2.5 billion. Besides this, he was also listed as one of the top 35 figures in the pharmaceutical sector by World Pharmaceutical Frontiers in 2008.
K. Nityananda Reddy
K. Nityananda Reddy – Founder, Vice Chairman and Managing Director of Aurobindo Pharma
Along with being the founder of Aurobindo Pharma, K. Nityananda Reddy serves as the Vice Chairman and Managing Director of Aurobindo Pharma. He has a Master’s degree in Science specialising in Chemistry. K. Nityananda oversees the overall operations of the Company and knows manufacturing technologies.
Aurobindo Pharma – Startup Story
The company was first started on 26th December 1896 as a private limited company. Its business took off in Puducherry in 1988–1989 with a single unit producing semi-synthetic penicillin (SSP).
Within a few years, Aurobindo established another facility at Pashmylaram, close to Hyderabad, to produce CMIC Chloride, a bulk drug intermediate.
In 1992, Aurobindo Pharma went public, and in 1995, it floated its shares on the Indian stock market. Later on, the company made an alliance with a UK-based company, Glaxo (India) to expand its business operations across UK boundaries. In 2001, it launched an exclusive anti-viral branch called Immune with the goal of educating and treating HIV/AIDS patients in the nation using preventative medications.
In 2005, Aurobindo strategically entered the high-end markets of the USA and Europe with generic formulations by taking part in the PEPFAR program, which was started by the US government. After five years, the company signed licencing and supply contracts with AstraZeneca, one of the top biopharmaceutical firms in the world, to provide many solid dosage and sterile products for developing countries.
It was in 2019, that Aurobindo started the establishment of a production plant for oral solids in Taizhou, China. In recent years, the company has made many establishments across other countries.
The mission of Aurobindo Pharma is, “To become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.”
Aurobindo’s vision reads, “To become a leading and an admired global pharma company, ranked in the top 25 by 2030”
Aurobindo Pharma – Name, Tagline, and Logo
Aurobindo Pharma – Logo and Tagline
The tagline of Aurobindo Pharma is, “Committed to healthier life!”
Aurobindo Pharma – Business Model
Thebusiness model of Aurobindo Pharma consists of three segments:
Generics/ Branded Generics
Product Out Licensing
Contract Manufacturing
The business of Aurobindo is present in over 150 countries. It has eight key formulation facilities in India and one each in US and Brazil.
Some of the different formulations offered by Aurobindo are:
Anti-bacterial like Penams, SSPS & Combinations, Quinolones
Central Nervous System (CNS) products like Anti-Alzheimers, Anti-Depressants
Cardiovascular (CVS) Products like Anti-Platelets, Beta Blockers, ACE Inhibitors
Other products like Anti Viral, Anti-Diabetics, Anti-Fungals, etc.
Aurobindo’s business includes a vertical integration that offers cutting-edge solutions. Its cost-effective medication development and significant manufacturing support help in the expansion from discovery to development and commercialization.
As mentioned, Aurobindo’s R&D Center has created goods and submitted over 200 ANDAs, around 124 product dossiers in the EU, and several dossiers in other nations, including Brazil, South Africa, Australia, and China. A multidisciplinary team of over 700 scientists working for excellence is housed in over 13,000 square metres at its R&D Center in Hyderabad.
Another key business unit of Aurobindo is AuroZymes. It is a biocatalysts division of Aurobindo Pharma Ltd. The biocatalysts are created and produced by AuroZymes for usage in the chemical and pharmaceutical industry. These biocatalysts were first created for internal usage, however, they are now accessible to Aurobindo’s clients. Through AuroZymes, Aurobindo helps develops a range of services to increase their client’s production as per their requirement.
AuroSource is also a crucial aspect of Aurobindo Pharma. It is the custom research and manufacturing division of Aurobindo. Through AuroSource, the company offers customer-centric project-based chemistry services.
Aurobindo Pharma’s business operations also include the subsidiary division of Aurobindo Pharma, Auro Peptides Ltd. It offers cutting-edge solutions from research to development and commercialization and cost-effective drug manufacturing.
Aurobindo Pharma is also known for its great CSR activities. The company has established an agency, Aurobindo Pharma Foundation in order to implement its welfare activities. Its welfare activities have proved to be beneficial for lakhs of individuals.
Aurobindo’s CSR Activities
Many areas of sustainable assistance are covered by Aurobindo’s sustainability charter in favour of preventive healthcare like making safe drinking water available, encouraging education, eradicating hunger, poverty, and malnutrition, environmental sustainability, setting up old-ages homes for elderly people, maintaining ecological balance, conversing natural resources, and many more.
Aurobindo Pharma Foundation
Through its foundation, the company has set up 70 Reverse Osmosis (RO) Water Purification Plant in many locations. It has also constructed hundreds of modern toilets in various government schools, colleges, stadiums, etc in Hyderabad and Telangana states. To create Open Defecation Free communities (ODF), the Aurobindo Pharma Foundation has backed the Integrated Household Latrine (IHHL) initiative in some states’ villages.
Aurobindo Pharma – Revenue Model
Aurobindo Pharma Limited Revenue from FY18 to FY22
It is reported that Aurobindo Pharma generates revenue by exporting its products to over 155 countries across the globe. Through this, around 90% of the company’s revenues are derived from international operations. As per the company’s annual report 2021-22, 85% of total revenue comes from formulations and the other 15% is from APIs. Aurobindo Pharma Limited reported revenue of 23,455.5 crore INR ($2.9 billion) for FY22.
One of the biggest challenges for Aurobindo was in the year 2019. The issue was when the US Food and Medicine Administration sent Aurobindo a warning notice, following an inspection of Aurobindo Pharma Limited’s Pydibhimavaram, Ranasthalam (Mandal), Srikakulam District, Andhra Pradesh drug manufacturing plant. The warning letter stated that its API’s manufacturing process was faulted and had significant deviations from current good manufacturing practices (CGMP).
In 2018, another challenge for Aurobindo was when the Dutch documentary television show ‘Zembla’ featured their manufacturing plant in Hyderabad. The show described charges brought against the business for allegedly harming the environment and providing inadequate working conditions for its employees in Hyderabad, India.
Aurobindo Pharma – Mergers and Acquisitions
Seven businesses have been acquired by Aurobindo Pharma. Veritaz was their most recent purchase, made on March 28, 2022. They paid 171 crore INR ($22.4 million) to purchase Veritaz. Veritaz is a Hyderabad-based company that offers products in anti-infective and pain-management therapeutic areas.
Recently, in August 2022, the company announced that it has completed the acquisition of 51% equity shares in GLS Pharma Limited for 28.05 crore INR. GLS Pharma operates in the oncology business and has become a subsidiary of Aurobindo Pharma. Aurobindo Pharma has an open call to buy the rest of the 49% stake in the company after three years but before five years from the current acquisition.
The acquisition details of Aurobindo Pharma are listed below:
Date
Acquiree Name
Amount
March 28, 2022
Veritaz
$22.4 million
September 6, 2018
Sandoz International
$900 million
January 9, 2017
Generis Farmacêutica
$142.9 million
November 12, 2014
Natrol
$133 million
September 13, 2013
Silicon Life Sciences
—
September 13, 2013
Hyacinths Pharma
—
August 17, 2009
Trident Life Sciences
$27.9 million
Aurobindo Pharma – Awards and Achievements
The awards and achievements of Aurobindo Pharma are:
At the Global Generics & Biosimilars Awards 2019, which were held in Frankfurt, Germany, Aurobindo won two prizes; Company of the Year and Acquisition of the Year.
Aurobindo Pharma received the “Outstanding Export Performance Award” from the Pharmaceuticals Export Promotion Council of India for the year 2008-09.
The State Labour Department of the Government of Andhra Pradesh awarded Aurobindo the ‘Best Management Award’ in 2005.
The company announced through its annual report 2021-22 that it intends to broaden its product line with high-value cancer, hormone, biosimilar, and innovative drug delivery methods including depot injections, inhalers, patches, and films. Given that the generic medication industry in these nations is very tiny, it has also set its sights on geographic development in new areas including Poland, Italy, Spain, the Czech Republic, Portugal, and France.
To increase its position in the hospital sector, the pharmaceutical company is also constructing an injectable plant specifically for Europe and emerging countries. It will soon begin submitting novel injectable drugs in FY23, with commercialization beginning as soon as in FY24.
Here’s what the Vice Chairman and Managing Director, K. Nithyananda Reddy say about global expansion, “We also intend to transfer a few products from Europe to the China facility. With a total target of reaching 40 products in China, if we are successful in realising our plans then there should be significant accretion to both our topline and bottom-line spreads”
FAQs
Who founded Aurobindo Pharma?
Aurobindo Pharma was founded by P. V. Ramprasad Reddy and K. Nityananda Reddy in the year 1986.
Where is the company Aurobindo located?
Aurobindo Pharma has its headquarters in Hyderabad, Telangana, India.
What is Aurobindo Pharma’s revenue 2022?
Aurobindo Pharma Limited reported revenue of $2.9 billion for FY22.
Is Aurobindo a generic?
Aurobindo Pharma is an Indian multinational pharmaceutical manufacturing company which is one of the largest producers of generic medicines in the world.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Cipla Limited.
Pharma industries are one of the most crucial industries as they are considered the largest contributors to a country’s economy. We know, that the pharma industries are responsible for creating several medicines. In India, pharmaceutical companies are growing at a rapid rate, which makes India among the top pharmaceutical exporting countries.
Pharmaceutical companies have made tremendous advancements in the field of biomedical science and offer numerous solutions to mankind with their innovative and effective medicines.
Cipla is one such Indian multinational pharmaceutical company that develops various medicines to treat different types of diseases. It was founded in 1935 and has its headquarters in Mumbai.
Read on to find out more about Cipla. In this article, you will come across Cipla’s startup story, its founders, business model, revenue growth, challenges faced, awards achieved by Cipla, and more.
The Indian multinational pharmaceutical business, Cipla Limited is based in Mumbai. Founded by Khwaja Abdul Hamied in 1935, the pharma company focuses on creating medications to treat a variety of illnesses, including asthma, cardiovascular diseases, arthritis, diabetes, depression, and many others.
Cipla aims to never stop working to make sure that patients in need have access to high-quality, reasonably priced medications. For the past eight decades, medical professionals and patients worldwide have trusted Cipla because of this.
Care has been the cornerstone on which Cipla as an organisation has been constructed, brick by brick. The company has expanded its footprint to 80+ markets and provides more than 1,500 medications across numerous therapeutic categories in 50+ dosage forms. Currently, Cipla is expanding its footmark in key areas including India, South Africa, and the United States as well as other developing nations’ economies in an effort to make healthcare more accessible globally. Cipla is also present in countries like – Kenya, Australia, South Africa, the USA, Europe, Malaysia, Morocco, Nepal, Sri Lanka, Uganda, and United Kingdom.
Cipla – Industry
The Indian pharmaceutical industry is the world’s 3rd largest by volume and 14th largest in terms of value. According to the Indian Economic Survey 2021, the domestic market is expected to grow 3 times in the next decade.
It is reported that India supplies around 20% of the generic medicines globally in terms of volume. As already mentioned, the Indian pharmaceuticals industry is among the top 10 for having the highest value of drugs and medicines during 2020.
Cipla – Founders and Team
Cipla Limited is founded by Dr. Khwaja Abdul Hamied in 1935.
Khwaja Abdul Hamied
Dr. Khwaja Abdul Hamied – Founder of Cipla Limited
Dr. Khwaja Abdul Hamied laid the foundation of Cipla in 1935. Dr. Hamied was born to Khwaja Abdul Ali and Masood Jahan Begum in Aligarh, Uttar Pradesh in 1898. He was a follower of M.K. Gandhi and also a founder professor along with Zakir Husain of Jamia Millia Islamia, Aligarh, which is now based in Delhi. Dr. Hamied received his undergraduate degree from Allahabad University, Uttar Pradesh, and his Master’s and Doctoral degrees from the Humboldt University of Berlin, Germany. Dr. Hamied was a scientist who opposed imperialism and was a nationalist and freedom fighter in India.
Dr. Khwaja Abdul Hamied started Cipla with a very strong aim, “Never again will India be starved of essential drugs.“
Yusuf Khwaja Hamied
Yusuf Khwaja Hamied – Non-Executive Chairman of Cipla Limited
Yusuf Khwaja Hamied is the Non-Executive Chairman of Cipla Limited. An Indian scientist and billionaire businessman, Yusuf took over the company after his father, Dr. Khwaja Abdul Hamied. His popularity is known outside the national boundaries as he is best recognised for fighting against powerful Western pharmaceutical companies to offer affordable generic AIDS medications and therapies for other illnesses that largely afflict people in developing nations. Additionally, he was chosen as a fellow of the Indian National Science Academy.
Umang Vohra
Umang Vohra – Global CEO of Cipla Limited
Umang Vohra is the Managing Director and Global CEO of Cipla Limited. He has done Bachelor of Engineering in Computer Science from M.S. Ramaiah Institute of Technology, Bengaluru, Karnataka and got his degree in Master of Business Administration from T.A.Pai Management Institute, Karnataka. Umang was also Head of the North America business at Dr Reddys Laboratories, and Manager, Financial Planning at Pepsico India.
The history of Cipla goes back to 1935 when Dr. Khwaja Adbul Hamied founded one of the leading pharma companies in India. Initially, the company was known as, ‘The Chemical, Industrial & Pharmaceutical Laboratories.’ Later on, in 1984, the company was named ‘Cipla Limited.’
It was in 1968 when Cipla’s revenue crossed over Rs 1 crores. Soon after, at Mumbai Central Headquarters, an ORG 2001 computer was installed by the company to streamline the payroll and financial accounting processes, saving 20 days of labour from seven people. Then in 1991, the turnover of Cipla crossed Rs 100 crores.
The first oral iron chelator in history, Deferiprone, was introduced by Cipla in 1995. Antiretrovirals for HIV treatment were made available by the company in 2001 for less than $350 per patient annually.
In order to give patients with real-time monitoring, coaching, and advice, Cipla has partnered with Wellthy Therapeutics in India and Brandmed in South Africa in 2019. This collaboration combines behavioural science, actual clinical evidence, and artificial intelligence.
During the covid-19 outbreak, the establishment of Maharashtra’s only pediatric isolation facility specifically for COVID-19 is supported by Cipla Foundation.
The company completed its 85 years on 17th August 2020. The Cipla Foundation is said to have given funds to set up a world-class chemistry research laboratory at the Indian Institute of Science Education and Research (IISER) Pune.
Now, the company has over 25,000 employees working in the organisation all over the world.
Cipla – Name, Logo, and Tagline
Cipla Limited – Logo and Tagline
The company was first established as ‘The Chemical Industrial & Pharmaceutical Laboratories Ltd. and then later changed its name to Cipla Limited in 1984.
Cipla goes by the slogan, “Caring for Life.”
Cipla – Mission and Vision
Cipla’s values include guiding and conduct in every conversation, organisational decision, and action of its employees.
The mission of Cipla is to be the top global healthcare provider, utilising innovation and technology to cater to all patients’ basic needs.
The mission and vision of the company in the words of Dr. Y K Hamied, Chairman Cipla, “Our work is not just making medicines. It is about making a difference.”
Cipla – Business Model
The business model of Cipla can be called a Generic Pharmaceutical Company (GPC) business model. Cipla is one of the largest pharmaceutical firms in India. The company operates in more than 80 countries and has 47 manufacturing facilities spread across the globe.
Cipla has a wide portfolio of drugs across therapies. Let’s take a look at what Cipla offers:
Therapies
Cipla offers various treatments for diseases like heart failure, MI, lipid abnormalities, angina, hypertension, arrhythmia, diabetes, and obesity.
Respiratory
Cipla has introduced products for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis (AR), and more recently other diseases such as Pulmonary Arterial Hypertension (PAH), lung cancer, and Idiopathic Pulmonary Fibrosis (IPF). Some of the common respiratory products by Cipla are Salbutamol tablets and Salbutamol inhalers.
HIV/AIDS
Cipla is dedicated to the cause of HIV/AIDS by staying true to its motto, ‘None shall be denied.’ To help eradicate AIDS, Cipla introduced the first ever prescribed 3-in-1 fixed-dose combination in the year 2001 (stavudine, lamivudine, and nevirapine). In contrast to the average annual cost of over $12,000 per patient in most developed nations, it was made available for around $350 per year. The WHO and FDA have also approved Cipla’s biggest selection of antiretroviral medications.
Oncology
Cipla was the first company in India to introduce the drugs Vincristine and Vinblastine in 1984. To provide free care for cancer patients who were nearing the end of their lives, the Cipla Palliative Care and Training Centre in Pune was founded in 1997. More than 11,000 patients and their families have received assistance from the Center over the years.
Urology
With products for BPH (Benign Prostatic Hyperplasia), prostate cancer, urinary stones, hypogonadism, and sexual dysfunction conditions, Cipla has a sizable presence in the field of urology.
Cardio Metabolism
Products like Propranolol, which was introduced in 1972, were the company’s first fight against heart problems. For diabetes, Cipla has introduced several pills like Metformin, Metformin plus Glimepiride, and Metformin plus Glimepiride plus Pioglitazone.
Cipla is present in nine essential pediatric therapeutic segments like Anti-bacterial, Gastrointestinal, Anti-asthmatics, Chelation therapies, etc.
Infectious Diseases & Critical Care
Cipla has products like Tazobactam + Pipercillin, Colistin, Vancomycin, Paracetamol Infusion, etc. to fight various types of infections caused by viruses or bacteria.
Hepatitis
Cipla has managed to produce drugs to treat diseases like Hepatitis B & C.
Women’s Health
Cipla launched Clominphene citrate for infertility in women in 1979. Since then, the company has created a range of products to improve the overall health of women. The company has medication to help women at every stage of their lives, from managing polycystic ovarian syndrome to maintaining early pregnancy, from reducing post-partum haemorrhage to hormone treatment, to addressing menopausal difficulties. It has expanded its global product offering for women’s health to a number of nations.
Ophthalmology
Cipla Ophthalmology is aimed at treating diseases like glaucoma, infective keratitis, and endophthalmitis in association with the All India Ophthalmology Society.
Cipla’s R&D main areas of interest were the creation of novel formulations, drug delivery methods, and APIs (active pharmaceutical ingredients). In addition, Cipla collaborates with other businesses on projects involving consultation, commissioning, engineering, project evaluation, quality control, know-how transfer, support, and plant supply.
Some of the major products under the label of Cipla are:
Cofsils – Provide relief from sore throat and cough
Ciphands – Range of hand sanitisers, hand rubs, and surface sprays.
Nicotex – A range of products to quit smoking.
CIPREMI – Gilead Sciences’ Remdesivir for emergency COVID-19 treatment for critical patients.
Cipla also offers many Covid-19 diagnostics products for easy accessibility. It has products like- CIPTest, CIPtest Plus, and ViraGEN.
Cipla Palliative Care and Training Centre
To treat patients who have a serious illnesses and support them with the best possible facilities and care. The company has teamed up with the government, public health institutions, local administration, NGOs, and frontline workers to treat and take care o people who were affected because of covid.
Cipla’s main area of focus is onhealth, education, skill development, and environmental sustainability & disaster response.
Cipla – Revenue Model
Cipla Limited Revenue from FY2016 to FY2022
Cipla mainly generates its revenue by selling active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products.
The company’s revenue for FY21-22 is $2.7 billion ( Rs 21,763 crores). This was nearly a 14% Y-o-Y growth in the revenue from $2.4 billion (Rs 19,160 crores) in FY20-21. The profit recorded by the company in FY21-22 stood at $315 million (Rs 2,517 crores) which was nearly a 4% increase from $301 million (Rs 2,405 crores) in FY20-21.
Cipla – Investments
As of 2022, Cipla has made four investments. Their most recent investment was on June 28, 2022, when GoApptiv raised ₹260 million. The other investments are:
Cipla has acquired six organizations. Their most recent acquisition was Mirren Pty Ltd. for $33 million on July 12, 2018. The other acquisitions are:
Acquiree Name
Date of Acquisition
Amount
Mirren Pty Ltd.
July 12, 2018
$33 million
Exelan Pharmaceuticals
September 4, 2015
$50 million
InvaGen Pharmaceuticals
September 4, 2015
$500 million
Quality Chemicals Ltd.
May 25, 2015
$30 million
Cipla Medpro South Africa Ltd.
July 16, 2013
$512 million
Meditab Specialities
Nov 23, 2011
$16.7 million
Cipla – Shareholding
Cipla Limited Shareholding Pattern 2022
The equity shares of Cipla are traded on the National Stock Exchange of India (CNX Nifty) and the Bombay Stock Exchange (BSE). The Luxembourg Stock Exchange lists its Global Depository Receipts (GDRs). The prominent shareholders of the company include the Promoter and Promoter Group, Foreign Institutional Investors, Indian Institutional Investors, GDR, and Others.
Cipla – Online and Social Media Presence
The company have a very influential social media presence. It can be seen from the number of social media accounts they have on popular platforms like:
Facebook Page – 78,712 followers
LinkedIn Page – 958,173 followers
Instagram Page – 9.9K followers
Twitter Page – 32.2K followers
YouTube – 8.63K subscribers
The followers and subscribers count are as of August 2022.
Cipla – Advertisements and Social Media Campaigns
Quite recently, Cipla has launched an ad on various digital mediums, TV, cinema, and social media platforms with their new brand ambassador Ayushmann Khurrana. The company through this advertisement wants to raise people’s awareness of the value of taking multivitamin pills daily. The brand wanted to capture people’s attention through Ayushmann about keeping oneself fit and having stamina and energy in day-to-day life.
Cipla Health Campaign starring Ayushmann Khurrana
Another major campaign by Cipla is the ‘Berok Zindagi campaign’ with hashtags like – #InhalerHainSahi and #SayYesToInhalers. There are many campaigns featuring different actors who share their stories of having asthma and how using an inhaler is absolutely safe and easy to use even for kids as well. With regard to this campaign, there is also a song that was launched with the song name ‘Inhalers Hain Sahi’. It is sung and composed by renowned music composer Amit Trivedi.
Cipla – Berok Zindagi Campaign
Cipla – Awards and Achievements
Here’s the list of major awards won by Cipla:
Cipla received Economic Times Family Business Award.
Cipla won the 4th India Logistics and Warehousing Excellence Awards 2022.
BW Businessworld featured Cipla amongst the Top 40 BW Most Sustainable Companies in India.
Cipla bags the first prize in the GOQii Corporate Challenge at an organisational level.
Cipla was recognised at the 35th Goa Statehood Day for contributing significantly to healthcare in the state of Goa.
ET Brand Equity Kaleido Awards 2022.
Best New Product Introduction/ Promotion in the U.S. Generic Industry – Cipla USA Inc.
Cipla won Silver in Public Awareness Campaign in Healthcare & Wellness Category – Berok Zindagi.
Cipla receives the India Pharma Leader of the Year Award.
Cipla receives US-INDIA Trade Award – “Pharma & Healthcare” Category.
Cipla won Bronze in Best Integrated Report (Large Company) Category – Cipla Integrated Report.
Cipla was recognised as an Industry Mover in the S&P Global Sustainability Yearbook 2022.
Cipla – Challenges / Controversies faced
Just like any business, Cipla had to go through some challenges and criticism. An over-the-counter emergency contraceptive medication known as the “i-pill” was introduced by the company in August 2007. The company faced a lot of objections because it could be purchased without a prescription and carried a significant amount of medication in each dose.
Presently, Cipla is planning to scale-up injectables with five packings in the USA. Additionally, it is also thinking to gear up and launching high-quality products for generic versions.
With the rising cases of monkeypox, Cipla is also looking for opportunities to tie up with different partners in combating the new virus.
FAQs
Who founded Cipla?
Khwaja Abdul Hamied founded Cipla Limited in the year 1935. The Indian pharma company has its headquarters in Mumbai, Maharashtra, India.
Who is the owner of the Cipla medicine company?
Yusuf Khwaja Hamied is the non-executive chairman and owner of the medicine company, Cipla Limited.
Who is Umang Vohra?
Umang Vohra is the current Managing Director and Global CEO of the Indian pharmaceutical company, Cipla Limited.
What is Cipla’s revenue in 2022?
Cipla Limited revenue for FY21-22 is $2.7 billion ( Rs 21,763 crores).
